Genetic epidemiologic studies on age-related maculopathy: a population-based approach by Klaver, C.C.W. (Caroline)
Genetic epidemiologic studies on 
age-related maculopathy 
A population-based approach 
Caroline C.W. Klaver 
Acknowledgments 
This study was supported by grants from the Nestor Stimulation Program for Geriatric 
Research in the Netherlands (Ministry of Health and Ministry of Education), Rijswijk; 
Topcon Europe BV., Capelle aId Ussel; the Netherlands Society for Prevention of 
Blindness, Amsterdam; Landelijke Stichting voor Blinden en Slechtzienden, Utrecht; 
Haagsch Oogheelkundig Fonds, The Hague; Stichting Blindenpenning, Amsterdam; 
Rotterdamse Vereniging voor Blindenbelangen, Rotterdam; Stichting 
Fondsenwervingsacties Volksgezondheid, The Hague; Stichting Bevordering van 
Volkskracht, Rotterdam; G.Ph. Verhagen Stichting, Rotterdam; Stichting voor Ooglijders.; 
Stichting Blindenhulp, The Hague; Stichting Physicotherapeutisch Instituut, Rotterdam; 
Optimix Foundation, Amsterdam; Stichting ROOS, Rotterdam. 
ISBN 90-9013411-5 
Genetic epidemiologic studies on age-related maculopathy. A population-based approach. 
C.C.W. Klaver 
Thesis Rotterdam 
© C.C.W. Klaver, 2000 
No part of this thesis may be reproduced or transmitted in any forlll or by any means 
without permission of the author. 
Printed by: 
Layout: 
Cover: 
Print Partners Ipskamp, The Netherlands 
Roger Wolfs 
Marja Wessels 
Genetic epidemiologic studies on 
age-related maculopathy 
A population-based approach 
Genetisch epidemiologische studies over 
leeftijds-gebonden maculopathie 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor aan 
de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof. Dr. P.W.C. Akkermans M.A. 
en volgens het besluit van het College voor Promoties. 
De openbare verdediging zal plaats vinden op 
woensdag 5 januari 2000 om 15.45 uur 
door 
Caroline Catharina Wilhelmina Klaver 
geboren te Dubbeldam 
Promotiecommissie 
Promotores: 
Ovel'ige leden: 
Prof. dr. P.T.V.M. de Jong 
Prof. dr. A. Bofman 
Dr. C.M. van Duijn 
Prof. R. Klein 
Prof. dr. G. van Rij 
Voor mijn ouders 
Publications and manuscripts based on the studies described in 
this thesis 
Chapter 2 
Klaver CCW, Vingerling JR, Hofman A, de Jong PTVM. AltersabiJlillgige 
Makuladegelleratioll. Kapitell. Epidemiologie. Springer-Verlag Berlin Heidelberg 1997: 1-20. 
Vingerling JR, Klaver CCW, Hofman A, de Jong PTVM. Epidemiology of age-related 
maculopathy. Epidellliol Rev 1995; 17:347-360. 
Chapter 3 
Klaver CCW, Assink JJM, Wolfs RCW, Vingerling JR, Stijnen T, Hofman A, de Jong PTVM. 
Incidence and progression of age-related maculopathy. The Rotterdam Study. Submitted. 
Chapter 4 
Klaver CCW, Wolfs RCW, Vingerling JR, Hofman A, de Jong PTVM. Age-specific 
prevalence and causes of blindness and visual impairment in an older population. The 
Rotterdam Study. Arch OphthalmoI1998;116:653-658. 
Chapter 5 
Klaver CCW, Wolfs RCW, Assink JJM, van Duijn CM, Hofman A, de Jong PTVM. Genetic 
risk of age-related maculopathy. Arch Ophthalmol 1998; 116: 1646-51. 
Chapter 6 
Assink JJM, Klaver CCW, Houwing-Duistermaat JJ, van Duijn CM, Hofman A, de Jong 
PTVM. Heterogeneity of the genetic risk in age-related maculopathy. Submitted. 
Chapter 7 
Klaver CCW, Kliffen M, van Duijn CM, Hofman A, Cruts M, Gmbbee DE, van Bmeckhoven 
C, de Jong PTVM. Genetic association of apolipopl'Otein E with age-related macular 
degeneration. Alii J HUIII Geuet 1998;63:200-206. 
Chapter 8 
Klaver CCW, Assink JJM, Vingerling JR, Hofman A, de Jong PTVM. Smoking is also 
associated with age-related macular degeneration in persons aged 85 years and older: The 
Rotterdam Study. Arch OphthalllloI1997;115:945 (letter). 
Chapter 9 
Klaver CCW, Ott A, Hofman A, Assink JJM, Breteler MMB, de Jong PTVM. Is age-related 
maculopathy associated with Alzheimer's disease? The Rotterdam Study. Alii J Epidellliol, in 
press. 
Chapter 10 
Klaver CCW, Assink J1M, Bergen AAB, van Duijn CM. ABCR and age-related macular 
degeneration (Technical Comment). Sciellce 1998;279: 1107. 
Contents 
Part 1 Backgrolllld 
Chapter I Aims of this thesis 3 
Chapter 2 Epidemiology of age-related maculopathy. 5 
A review 
Part II Disease !reqllellcy alld impact 39 
Chapter 3 Incidence and progression of age-related maculopathy. 41 
The Rotterdam Study 
Chapter 4 Age-specific prevalence and causes of blindness 55 
and visual impairment in an older population. 
The Rotterdam Study 
Part III Gelletic risk of age-related maclliopatlly 69 
Chapter 5 Genetic risk of age-related maculopathy. 71 
A population-based familial aggregation study 
Chapter 6 Heterogeneity of the genetic risk in 85 
age-related maculopathy 
Chapter 7 Genetic association of apolipoprotein E with 95 
age-related macular degeneration 
Part IV Ellvirollmelltal risk alld comorbidit), 107 
Chapter 8 Smoking is also associated with age-related macular 109 
degeneration in persons aged 85 years and over 
Chapter 9 Is age-related maculopathy associated with 113 
Alzheimer's disease 7 The Rotterdam Study 
Part V Gelleral disCllssioll alld slllllllwr)' 123 
Chapter 10 General discussion 125 
Chapter II Summary I Samenvatting 139 
Chapter 12 Dankwoord 143 
Curriculum Vitae 147 
List of publications 149 
Abbreviations 
ABCR 
AD 
AMD 
Ape 
APOE 
App 
ApoE 
ARM 
CI 
95% CI 
CNV 
IR 
OR 
RPE 
RR 
A TP-binding cassette transporter gene 
Alzheimer's disease 
Age-related macular degeneration 
Attributable proportion in the exposed 
Apolipoprotein E (gene) 
Attributable proportiOil in the population 
Apolipoprotein E (protein) 
Age-related maculopathy 
Cumulative incidence 
95% Confidence interval 
Choroidalneovascularization 
Incidence rate 
Odds ratio 
Retinal pigment epithelium 
Relative risk 
Part I 
Background 

Chapter 
1 
Aims of this thesis 
The western world is aging rapidly. In the Netherlands, the current mean life 
expectancy for men and women is 74.6 and 80.4 years, respectively, and those over 65 
years of age comprise 13.6% of the total population.' This proportion of elderly is 
expected to increase considerably within the coming years, and this will lead to higher 
frequencies of diseases. Age-related maculopathy (ARM) is one of those frequent 
geriatric diseases. It is an eye disease ultimately leading to blindness. The prevalence 
of the clinical end stages of this disorder range from 1 % in those aged 60 years of age 
to 10% in those aged 85 years and older. At least 60000 Dutch subjects' are severely 
affected by these end stages, also called age-related macular degeneration (AMD). 
AMD has a great impact on visual function and the performance of daily tasks, in 
particular because there are still no means for long term restoration of vision. 
During the last decade there has been steadily increasing research activity 
investigating the disease etiology. It became better known that the pathogenesis was 
complex with a variety of risk factors involved. Family reports and twin studies 
pointed to a genetic background, and epidemiologic studies suggested environmental 
influences from vascular and dietmy factors, sunlight and smoking. However, findings 
were not unequivocal, and the evidence on most of these relations was insufficient and 
inconclusive. This called for more extensive research into the causes of ARM. 
This thesis aimed to answer the following questions: 
Pal'l I: What is the current genetic epidemiologic knowledge on ARM? 
Pari Jl: What is the incidence of AMD, what is the natural course of the disease, 
and what is the relation with visual impairment? 
ParlllI: To what extent is ARM genetically determined, and which genetic factors 
may be involved? 
Pal'l IV: Are environmental factors important in the pathogenesis, and is ARM 
associated with other disorders? 
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We used a genetic epidemiologic approach to investigate these issues. All studies 
were based on the Rotterdam Study, a prospective population-based cohort study of 
subjects aged 55 years and over taking place in Ommoord, a suburb of Rotterdam. The 
baseline phase of this study was conducted from 1989 to 1993; the first follow up from 
1993 to 1994. A family study originating from the Rotterdam Study was conducted 
from 1994 to 1996. 
References 
I. Statistisch laarboek 1999; Centraal Bureau voor de Statistiek. VoorburgIHeerien. 1999. ISBN: 
903572635 9. 
2, Estimated using data from the Statistisch Jaal'boek 1999 and the Rotterdam Study, 
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Epidemiology of age-related maculopathy 
A review 
INTRODUCTION 
The late stage of age-related maculopathy, also referred to as age-related macular 
degeneration, is the leading cause of permanent visual impairment among the elderly 
in western countries.'·4 The loss of vision is a result of degeneration of the 
photoreceptors in the macular area, which occurs when the retinal pigment epithelium 
cells with which they are associated deteriorate and die. Useful intervention is limited 
to only a minority of patients.5•6 Since the previous reviews concerning the 
epidemiology of ARM by Ferris in 1983,' and by ourselves in 1995,' many more 
investigations have focussed on this disease in an attempt to find etiological clues. This 
chapter is based on our initial review, but also contains an update ofthe literahlre that 
has appeared since its publication in 1995. We will review the current epidemiological 
knowledge concerning ARM and discuss diagnosis, frequency, risk factors and 
prognosis. 
DIAGNOSIS 
Diagnostic criteria 
Age-related maculopathy affects the center ofthe retina and choroid in the posterior 
pole of the eye. Generally, it is considered to be present when one or more of the 
following changes are visible in the macular area: 
large drusen: yellow deposits below the retinal pigment epithelial cells; 
hyper- and hypopigmentary changes of the retinal pigment epithelium; 
atrophic AMD, also known as geographic atrophy: well defined areas of atrophy 
of the retinal pigment epithelium and choriocapillaris; 
5 
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neovascular AMD: serous or hemorrhagic detachment of the pigment 
epithelium, choroidal neovascularization and subsequent scarring of the macular 
area. 
Although these changes are all manifestations of the disease and associated with 
increasing age, they show a large range of variety, and for years this has been an 
obstacle for a uniform definition and classification system. Early epidemiological 
studies have included decreased central visual acuity as one ofthe diagnostic criteria. 
Recently, however, three grading systems have been developed to classify ARM on 
color photographs of the macula lutea without implication of visual acuity."" The 
definitions of these grading systems are summarized in Table 1. In brief, the system 
of Bressler et al. consists of four categories, and at each step from categOly one to four, 
the system leaves out less severe abnormalities. The Wisconsin Age-Related 
Maculopathy Grading System provides a detailed grading of each abnormality with 
respect to its size, area and location. It defines early and late stages of ARM.12 
Presently, an international study group has developed a classification system to 
facilitate comparison of data between the various epidemiological studies. This system 
defines ARM as all manifestations of this disorder and AMD as the late stages: 
atrophic or neovascular macular degeneration. For the purpose of this review and this 
thesis, we will maintain the terminology of the International System. 
Differential diagnosis 
D11Isen must be differentiated from other conditions with white spots in the macula like 
hard exudates, cotton wool spots and retinal pigment epithelium hypopigmentations 
such as in fundus flavimaculatus and fundus albipunctatus. Pigmentaty changes can 
also be seen in combination with other abnormal processes in the macular area which 
are not directly related to ARM, like those accompanying chorioretinal scars due to 
chorioretinitis, trauma or laser photocoagulation. 
Any chorioretinal inflammation or scar may result in the growth of a subretinal 
neovascular membrane. Therefore, neovascular AMD sometimes resembles similar 
conditions in myopic macular degeneration, pseudoxanthoma elasticum, Paget's 
disease, presumed ocular histoplasmosis syndrome, toxoplasmosis, central areolar 
choroidal sclerosis,\3, 14 laser photocoagulation scars and traumatic, inflammatory, 
toxic, and congenital processes. \0 In general, these disorders must be excluded before 
a diagnosis of ARM can be made, 
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FREQUENCY 
Prevalence 
Estimation of the occurrence of ARM is not only necessmy for assessing the need for 
ophthalmological care, but comparison of frequency figures from different populations 
may also suggest etiological clues to the disease. Population-based studies on the 
prevalence of ARM were conducted in the United States, Europe, Australia, and New 
Zealand (Table 2). Studies from Framingham,' Gisborne,15 Melton Mowbray,16 
Copenhagen,17 the National Health and Nutrition Examination Survey (NHANES)18 
and Iceland '9 estimated the prevalence of any type of ARM based on 
ophthalmoscopical assessment of macular changes with the requirement of central 
visual loss. As is shown in Figure I, the prevalence estimates in these studies vmy 
considerably. The studies from Chesapeake Bay; Beaver Dam," and Blue Mountain 
21 based their data on photographic grading of macular changes and did not require 
visual loss, which may explain why their prevalence estimates for any type of ARM 
are higher (Figure I). Whatever definition or method of diagnosis, all estimates show 
a strong rise with age, and a reasonable overall prevalence for any type of ARM in the 
age-groups 65-74 years and 75-84 years is 20 and 35 percent, respectively. 
Separate prevalence estimates of atrophic or neovascular AMD are available from 
the studies in Framingham, Iceland, Chesapeake Bay, Beaver Dam, Rotterdam, 20 Blue 
Mountain,21 Colorado,22 and Southern Italy 23 (Figure 2). The first two studies based 
their estimates only on neovascular AMD, while the latter also included atrophic 
AMD. These prevalence estimates show less variation than with inclusion of drusen 
and pigmentmy changes, and the estimates show an exponential increase after the age 
of70 years. A reasonable overall prevalence ofneovascular and/or atrophic AMD in 
the age-groups 65-74 years and 75-84 years is I and 5 percent, respectively. Although 
no other studies showed any prevalence difference in gender, the Blue Mountain Eye 
Study21 and the Beaver Dam Eye Study" noted that women had a higher prevalence 
of AMD than men. 
Incidence 
Recently, two population-based studies reported data on the incidence of ARM. The 
Chesapeake Bay Waterman Study 24 estimated a 5-year cumulative incidence of 
neovascular macular degeneration of2% (one of 50 participants) in men over 70 years 
of age, while none had developed atrophic macular degeneration during this follow up 
time. The Beaver Dam Study" also repOlied the 5-year incidence of ARM and macular 
7 
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degeneration; in subjects aged 65-74 years the 5-year cumulative incidence of atrophic 
or neovascular AMD was 1.3%, while in subjects over 75 years the incidence of these 
late stages was 5.4%. As in their prevalence study, they repOlied that AMD developed 
more often in women than in men, and the ratio neovascular AMD versus atrophic 
AMD was 2: I. Other population-based studies are currently performing follow up 
studies and their incidence data are expected in the coming years. 
Table 1. Classification of ARM 
8 
Bressler, et al.9 
Grade I: Presence of grade 4, 3 or 
2. or eyes with at least five small 
drusen within 1,500 ~1I11 of the 
foveal center or allensl ten small 
drusen between 1,500 and 3,000 
pm from the foveal center. 
Grade 2: Presence of grade 4 or 3, 
or eyes with;:.. 20 small drusen 
within 1,500 Jim orthe foveal 
center, 
Grade 3: Presence of grade 4, or 
eyes with large or confluent 
drusen, or eyes with focal 
hyperpigmenlalion of the retinal 
pigment epithelium. 
Grade 4: Geographic atrophy of 
the retinal pigment epithelium or 
exudative changes (eg. choroidal 
neovaseularization, detachment of 
the retinal pigment epithelium, 
and discifonn scarring). 
Wisconsin Agc~rclatcd 
Maculopathy Grading System.IO 
Early ARM: Soft indistinct or 
reticular dnlsen or any soft or 
reticular drusen with retinal 
pigment epithelium degeneration 
or increased retinal pigment in the 
macular area and the absence of 
late ARM. 
Late ARM: 
Signs of exudative AMD or 
geographic atrophy. 
The International Age-Related 
Maculopathy Study Group,ll 
ARM: All fealures of the disease 
excluding hard drusen. Drusen 
and pigmentary changes are 
characterized by type, number, 
size, and area. 
AMD: the end stages of ARM 
subdivided in atrophic AMD, i.e., 
geographic atrophy, and 
ncovascular (exudative) AMD. 
Table 2. Population-based cobort studies of ARM 
Site (reference no.) Criteria for diagnosis Age range Sample size Response (yr) rate 
Fnuningham (1) Ophthalmoscopy: drusen~ pigment disturbances; atrophic or neovascular macular degeneration, 52· 84 2675 67 
visual acuity 
NHANES(18) Ophthalmoscopy: drusen: pigment disturbances; atrophic or neovascular macular degeneration. 45·74 1413 72 
visual acuity 
Gisbom (15) Ophthalmoscopy: drusen; pigment disturbances: atrophic or neovascular macular degeneration, 65+ 481 82 
visual acuity 
Melton Mowbray (16) Ophthalmoscopy: drusen: pigment disturbances: atrophic or neovascular macular degeneration. 75 + 484 72 
visual acuity 
Iceland (19) Ophthalmoscopy: drusen: pigment disturbances; atrophic or neovascular macular degeneration. 43 + 751 81 
visual acuity 
Copenhagen (17) Ophthalmoscopy: drusen; pigment disturbances; atrophic or neovascular macular degeneration. 60· 79 1000 71 
visual acuity 
Chesapeake Bay (9) Photography: drusen. number. size and distinction of borders; focal hyperpigmentations~ non- 30 - 95 777 70 
geographic atrophy; atrophic or neovascular macular degeneration. 
Beaver Darn (12) Photography: drusen area. number. size and distinction ofborders~ increased or decreased 43 ·84 4926 83 
retinal pigrnen~ atrophic or neovascular macular degeneration. 
Rotterdam (20) Photography: drusen number and size; increased or decreased retinal pigment~ atrophic or 55 + 7583 78 
neovascular macular degeneration. 
Blue Mountain (21) Photography: drusen area. number, size and distinction of borders; increased or decreased 49 + 3654 82 
retinal pigment; atrophic or neovascular macular degeneration. 
Chapter 2 
Prevalence (%) 
60 
50 
40 
30 
20 
10 
o 
45 
----.-
--+---
-6-
---
--B---
--+---
-Ir-
---B--
50 
Framingham 
NHANES 
Melton Mowbray 
Iceland 
Gisborne 
Chesapeake Bay 
Copenhagen 
Beaver Dam 
55 60 65 70 
Age (years) 
Figure 1. Age-specific prevalellce of AMD (aI/types) 
Methodological considerations 
75 80 85 90 
The difference in definitions and methodology between studies hampers the 
comparison of prevalence data. In the studies from Framingham, NHANES, Gisborne, 
Iceland and Copenhagen, the diagnosis of ARM was only made·in patients with central 
visual loss. This led to lower prevalence rates than the estimates from Chesapeake Bay, 
Beaver Dam, Rotterdam, and Blue Mountain, which did not use this criterium. In 
addition, the fonner studies based the diagnosis on clinical examination, whereas the 
latter based their grading on fundus photographs. It is known that the frequency of 
drusen is generally underestimated with clinical ophthalmoscopy, which may be an 
extra reason for the higher prevalence of ARM in these studies. The Chesapeake Bay 
Waterman Study was designed to study the relation between sunlight exposure and eye 
diseases. The study population consisted of a selected group of fishermen and this may 
have influenced the prevalence rate. Despite these differences, however, there was a 
similarity in trends: all studies showed a rise of prevalence with increasing age (Figure 
1 ). 
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The comparison of the occurrence of end stages of ARM is also hampered by 
differences. In the studies from Framingham and Iceland, only the prevalence of 
neovascular AMD was reported. Atrophic AMD was pooled with dl1lsen and 
pigmentaty changes in these studies. In Chesapeake Bay, Beaver Dam, Rotterdam, and 
Blue Mountain, atrophic and neovascular AMD were pooled resulting in a higher 
estimate of prevalence. The differences between prevalences in these studies are 
therefore likely to be the result of differences in methodology and definition. 
RISK FACTORS 
A number of case-control and cross-sectional studies has focussed on the etiology of 
ARM. The main findings are summarized in Tables 2, 3 and 4. A point of 
II 
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consideration is that most results were based on prevalent cases, having its well-known 
limitations like selection bias and recall bias which may lead to spurious associations." 
In addition, the inclusion criteria for cases varied a great deal in the studies. Most 
studies included early and late stages of ARM. The results of these studies remain, 
therefore, to be confirmed in follow-up studies based on well-defined incident cases 
in which the exposure status is measured before onset of disease. 
The putative risk factors that will be discussed are family histOlY and genetic 
factors, ophthalmological characteristics, cardiovascular disease, and environmental 
exposures. 
Genetic factol's 
Famify studies 
While Hutchinson and Tay have observed familial occurrence of ARM as early as 
1875,27 the disease has only recently become the subject of extensive genetic 
investigations. Familial aggregation of dmsen has been reported by several studies. 
Early pedigree reports D."-30 have used different terms to describe the familial dmsen 
such as Doyne's honeycomb choroiditis, Tay's central guttate choroiditis, Holthouse-
Batten's superficial choroiditis and MaHatia Levantinese. An autosomal dominant trait 
was suggested for these familial dmsen, and they were considered to be different from 
dmsen occurring as a consequence of age." However, Gass postulated in 1973 D that 
there was only one entity of drusen, all being manifestations of a heredodegenerative 
disorder. Evidence for a familial predisposition of dmsen was found by a study which 
compared 53 sibling-pairs and 50 spouse-pairs for concordance of dmsen." The 
investigators found a significantly higher correlation of number and density of dmsen 
between siblings than between spouses. 
Family studies incorporating the late stages of ARM have received comparatively 
less attention. Two studies found a positive family history of macular disease in 
patients with dntsen or pigmentmy changes and/or atrophic and neovascular macular 
degeneration."·33 Because the majority of these family data was ascertained by 
interview alone, they should be intelpreted with caution, since anamnestic histOlY of 
an eye disease is unreliable.34 Observations in twins led to three case-reports 35-37 of 
identical twins having atrophic and/or neovascular macular degeneration and a study 
of nine monozygotic twin pairs" having a high concordance in either extensive dmsen 
or AMD. Selection bias or environmental factors may have played a role, but the 
striking similarity of fundus appearances in each twin pair suggests an increased 
genetic susceptibility in at least some of the patients. In a more extensive twin study, 
Meyers et al. 39 compared concordance in presence or absence of any type of ARM in 
12 
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98 monozygotic and 38 dizygotic twin pairs, who were predominantly ascetiained 
through twin organizations. Of the affected twin pairs, all (25/25) monozygotic twin 
pairs were concordant, while 42% (5/12) of dizygotic pairs were concordant. The 
numbers of affected twins in this study was low and skewed towards the monozygotic 
ones, therefore, the interpretation ofthese data should be somewhat conservative. More 
twin studies are currently underway. 
Mode of inheritance was investigated by a segregation analysis of data from the 
population-based Beaver Dam study.40 This study included 546 sibships with at least 
two members, and sibling correlations were calculated for age-dependent maculopathy 
scores. The authors concluded that a single major gene could account for -55% of the 
total variability in ARM. A point of consideration in the interpretation of these data is 
that the genetic models which were compared were three variations of Mendelian 
dominant inheritance and one more general transmission model. Theoretically, there 
are numerous possibilities of segregation in complex genetic disorders, and the choice 
of Mendelian models to test for in such an analysis is arbitrary. 
Silvestri 41 was the first to study familial aggregation of ARM in a case-control 
setting, cases being siblings of36 patients with 'dry' and exudative AMD, and controls 
being siblings of 36 patients undergoing a cataract operation. In this shtdy, the 
estimated odds ratio for first degree relatives to develop any type of ARM was 
estimated to be 19.3. In another clinic-based familial aggregation study, Seddon et al. 42 
compared the medical records of first degree relatives of 119 probands with extensive 
drusen or atrophic or neovascular macular degeneration with the records of first degree 
relatives of 72 control probands. This shldy estimated a much lower odds ratio of2.4 
(95% CI 1.2, 4.7) for first degree relatives. Possible explanations for this large 
difference in familial risk are the high chance of selection bias with hospital-derived 
probands, the large range of ARM features which were combined, and the use of 
family history, medical charts, and self-report for diagnosis. 
Thusfar, only one shldy investigated the phenotypic variation in affected families. 
De la Paz 43 examined the appearance of the macula in eight families with multiple 
affected individuals, and found a broad spectrum of fundus features within each of 
these families. This implies that genotype-phenotype correlations in ARM may be 
rather low. 
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Table 3. Case-control studies of ARM 
Site (reference 
no.) 
Fundus abnormalities 
Malzman (68) 
Delaney (80) 
Hyman (33) 
Blumonlmmz (82) 
EDCCSG (65) 
Cases 
Age-related maculopatby, not specified. 
visual acuity < 20/30 
Drusen. pigment clumping. neovascular 
macular degeneration. visual acuity <20130 
Drusen andlor more severe macular 
degeneration with some visual loss 
Neovascular macular degeneration 
Neovascular macular degeneration 
Controls 
Age and sex matched ophthalmological 
patients without age-related maculopathy 
Age and sex matched ophthalmological 
patients without age-related maculopathy 
Age and sex matched ophthalmological 
patients without age-related maculopatby or 
other neovascular retinal diseases 
15 partners and 8 age and sex matched 
others without neovascular macular 
degeneration or more than 10 macular 
drusen 
Residents of clinic area without neovascu1ar 
macular degeneration or drusen and 6/6 
visual acuity 
Grading method 
Ophthalmoscopy 
Ophthalmoscopy 
Photography 
Not 
specified 
Photography 
Age range 
(yr) 
52·88 
50+ 
< 85 
Not 
specified 
55·80 
Sample size 
(case/control) 
30130 
50/50 
228/237 
26123 
4211615 
Table 4. Risk factors for ARM 
Study (reference no.) 
Hyperopia 
Framingham (83) 
Malzman (68) 0 
Delaney (80) 0 
Hyman (33) 0 
Blumenkranz (82) 2.0 (0.5-6.2) 
Chesapeake Bay (63.128) 
Copenhagen (17.64) 
Beaver Dam (85.116.129) 0.2 (0.1-0.8) 
EDCCSG (65) 1.7 (1.1-2.6) 
Rotterdam (86,103,117) 1.9 (0.5-5.7) 
Blue Mouotain (70,118,130) 0.5 (0.2-1.5) 
* Odds ratio's with 95% confidence intervals in parentheses. 
* Blue light. 
II Leisure time in summer. 
rusk factor . 
Blue/light iris Cardiovascular Sunlight 
color disease 
Hypertension Smoking 
ex~osure 
0 1.4 (1.1-1.7) 
NS 1.3 (NS) NS 
204 (1.0-5.9) 6.1 (2.1-18.5) 
3.5 (1.7-6.6) 1.7 (1.1-2.7) 1.2 (0.8-1.9) 
0.7 (0.2-2.3) 4.0 (004-102) 0.6 (0.1-4.7) 1.3 (0.3-4.4) 
1.1 (0.6-2.0) 0.6 (0.4-1.1) 1.4 (1.0-1.9)' 
0.6 (0.3-1.1) 0.8 (NS) 2.4 (p<0.01) 
0.6 (0.3-1.3) 0.7 (0.3-1.4) 0.8 (0.1-5.5) 2.5 (1.0-6.2)' 2.2 (1.1-4.3)' 
1.1 (0.7-1.7) 1.1 (0.8-1.5) NS 2.8 (1.8-4.2) 1.1 (0.7-1.7)' 
0.6 (0.3-1.1) 2.5 (1.4-4.5)' 0.9 (0.6-1.4) 2.6 (1.5-4.8) 
1.7 (1.0-2.9) 1.4 (0.7-2.9) 1.1 (0.6-1.8) 504 (2.4-12.4) 
NS: Not Significant, but point estimate and confidence intervals unpublished. 
§ Women. 
11" Atherosclerotic plaques in common carotid artery. 
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Racial varia/ion 
Difference in genetic susceptibility explains part of the racial disparities in the 
frequency of a disease. For years, the clinical impression has been that ARM is rare in 
blacks. Only few studies have focussed on this issue. Gregor et al. 44 compared 
frequency of ARM between 1000 blacks in South Africa and 380 caucasians in 
England. All were 'consecutive' hospital outpatients. Blacks had a significantly lower 
frequency ofthe late stages of ARM (0.1 % compared to 3.5% among the caucasians). 
Later, Taylor" reported that ARM was a rare cause of blindness in elderly Australian 
Aborigines. A recent study carried out in Barbados among 3444 blacks found a 
prevalence of AMD of 0.6%.46 Although prevalence was much lower in these blacks 
than in caucasians from Western countries, these studies did not examine a 
considerable number of caucasians from the same area. Therefore, environmental 
differences could have affected the results. Data from the third NHANES survey47, 
which represents the various populations living in the U.S., showed that racial 
differences vaty by age. Compared to blacks, caucasians more often developed ARM 
in the age-category over 60 years, but less often in the younger age-categories, giving 
the impression that blacks have an earlier onset. On the other hand, the Baltimore Eye 
Survey" compared causes of blindness among 2395 blacks and 2913 caucasians and 
found that blindness due to AMD only occurred in Caucasians. The Colorado-
Wisconsin Study 22 also found the late stages to be extremely rare among Hispanic 
Americans, and the prevalence difference with Caucasians did not change after 
controlling for known risk factors as smoking and cardiovascular disease. All studies 
suggest a racial variation of the frequency of age-related maculopathy, but especially 
the latter study favours a racial difference in genetic susceptibility. 
Genes and loci 
ARM research has only recently focussed on molecular genetics with the aim to map 
this disease, to identify genetic forms of the disease, and to create etiologic insights. 
Until now, there have been vety few positive results. The first important candidate 
gene that was investigated is the tissue inhibitor of metalloproteinases-3 gene (TIMP-
3) on chromosome 22, which was identified in autosomal dominant Sorsby's fundus 
dystrophy, a dystrophy that phenotypically resembles AMD.49 De la Paz 50 studied 
TIMP-3 in 38 multiplex families with extensive intermediate dnrsen, large drusen, 
geographic atrophy or evidence of exudative AMD, and excluded any linkage with 
ARM within an area of 10 cM around TIMP-3. Another candidate gene was the 
photoreceptor cell-specific ATP-binding transporter gene (ABCR), located on 
chromosome Ip21, which is involved in Stargardt disease (STGD).51 AlIikmets et al. 
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suggested that this gene was implicated in ARM 52 after observing that certain 
variations of ABCR were more frequent in 167 patients than in 220 controls. The 
findings appeared to be controversial: there were critical comments regarding the 
classification of ARM, the selection of controls, and the statistical methodology. 53. 54 
Stone et al." did find allelic variation of ABCR in Stargardt disease, but he could not 
confirm an association with ARM. To fully comprehend the relevance of the ABCR 
gene for the etiology of ARM, larger studies are needed in well-defined patients and 
controls. 
Recently, Klein et al." identified a large family in which ARM was segregating as 
an autosomal dominant trait. In the 10 affected family members ARM was expressed 
by the presence of large, soft, confluent drusen accompanied by varying degrees of 
retinal pigment epithelial degeneration and/or geographic atrophy. In this family, the 
disease locus was mapped to chromosome I q25-q31. 
Ocular risk factors 
Iris color 
A protective effect of a dark pigmented iris on age-related maculopathy has been 
suggested after a low prevalence of the disease was repOlied in black Africans." 
Cumulative light exposure may have a harmful effect on the photoreceptors and retinal 
pigment epitheliUlll."-61 A dark iris is possibly protecting the retina better against light 
exposure than a light iris. Initially, two case-control studies reported a protective effect 
ofa dark iris for ARM, JJ.62 but this was not confirmed in later studies."-" Holz et al.66 
repotied no association with light iris color, but mentioned that self-repotied decrease 
of iris pigmentation during life was associated with ARM. The inconsistency of data 
and the absence of an association in the population-based studies suggests a small 
effect, if any. Sandberg et al.67 reported that light iris pigmentation is associated with 
a more extensive disease in patients with neovascular macular degeneration. Because 
referrals are generally related to severity of symptoms, this may explain some of the 
inconsistent findings ofthe clinic-based studies on this matter. 
Refi'aclive error 
A possible association of hyperopia and ARM was first suggested by Maltzman et al." 
Later, four case-control studies confirmed this finding."·.,·,,·69 Hyman pointed out that 
selection bias could have influenced that observation, 33 because the control group may 
have overrepresented myopic subjects. The control group in another study consisted 
ofnon-neovascular AMD cases.69 The authors suggested that this control group may 
have comprised a larger proportion of cataract patients, which can result in myopia due 
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to lens swelling and therefore may have led to a spurious association with hyperopia. 
A recent report from the population-based Blue Mountain Eye Study found a weak 
relation between hyperopia and early ARM, but not with the late stages. 70 The 
reference group consisted of population-based emmetropic subjects, so selection bias 
is not an explanation for these data. A supportive theOlY of the association between 
hyperopia and ARM may be that hyperopics have a thicker sclera than emmetropics, 
which may influence choroidal vascular flow and the supply of nutrients to the retina. 
However, considering the inconclusive associations, it is still doubtful whether an 
association between hyperopia and ARM really exists. 
Cataract alld cataract extractioll 
The data regarding the association between cataract and ARM have been 
inconsistent.7I •73 In Beaver Dam, there was an association between presence of nuclear 
cataract and prevalent early ARM at baseline, but this finding could not be replicated 
with incident early or late ARM at 5-year follow Up.74 An increased risk of ARM after 
cataract extraction was first suggested by a histopathological study." This finding was 
confirmed later by Pollack et al. 76 in a clinic-based setting. He studied 47 patients with 
bilateral early ARM after cataract extraction on one eye, and found that the operated 
eye was much more at risk of subretinalneovascularization than the unoperated eye. 
The 5-year incidence data of Beaver Dam 74 added to the evidence for this relation. In 
this study, the odds ratio of incident late ARM for operated eyes was 2.8 (95% CI 1.03, 
7.63). The finding is of great clinical importance, for it suggests a conservative policy 
towards subjects with early ARM and cataract. Possible explanations for the 
association, apart from detection bias, are photic injury during operation, traumatic 
ruptures in Bruch's membrane, or inflammatory changes after surgery. 
Vascular risk factors 
One hypothesis for the pathogenesis of ARM is that vascular disease affects the 
choriocapillaris. This may result in decreased flow or passage of nutrients.77-79 The 
issue was examined in various ways, either by investigating cardiovascular history data 
or by direct measurements. 
HistOlY of cardiovascular disease 
Conflicting reports have been published about the association between ARM and a 
history of cardiovascular disease: several case-control studies found a positive 
association,33.so.,! whereas others did not."·6'.S2 Self reported history of cardiovascular 
disease, however, is potentially biased by misclassification, making it more difficult 
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to detect an association. 
Hypertellsioll 
Sperduto et a!. reported a small and consistent association between ARM and 
hypertension as determined 25 years prior to the diagnosis maculopathy in the 
Framingham Heart and Eye Study.'3 The association was stronger with increased 
duration of systemic hypertension. Vinding, however, did not find an association 
between blood pressure levels and ARM itl a four-year follow-up in the Copenhagen 
Heart Study." Other studies used blood pressure levels taken at the time of eye 
examination, and reported a positive association with increased systolic blood 
pressure. IS.65 No associations with blood pressure, hypertension and prevalent ARM 
were found in Beaver Dam," Rotterdam,86 Blue Mountains,87 Colorado," London,88 
01' Oulu.89 Beaver Dam'· did find an association between uncontrolled hypetiension 
and incident neovascular ARM (OR 2.1,95% CI 0.5, 8.1). In sununary, the association 
with blood pressure is inconsistent, and as yet unsettled. 
Atherosclerosis 
In the Rotterdam Study, VingerJing et al. 86 found that plaques in the carotid bifurcation 
(OR 4.7,95% CI 1.8,22.2) and plaques in the common artelY (OR 2.5,95% CI lA, 
4.5) were associated with AMD in subjects younger than 85 years. Lower extremity 
disease was associated with an OR 2.5 (95% CI lA, 4.5). The Beaver Dam Study'· 
found that high pulse pressure, a presumed indicator of atherosclerosis, was associated 
with a 30% (95% CI 1.02, 1.65 per 10 mmHg) increased 5-year incidence of 
neovascular ARM. The Atherosclerosis Risk in Communities Study reported that 
carotid artelY plaques and focal retinal arteriolar narl'Owing were associated with RPE-
depigmentation, but not with eady or late ARM.'os More studies are needed to explore 
this association in detail. 
Hyperglycemia alld diabetes 
Hyperglycemia has been reported to affect the choroidal circulation, Bl1lch's 
membrane, and the RPE.'I.96 A relation between hyperglycemia and ARM has 
therefore been proposed. A number of case-control 33.65.68.81.82 and two population-based 
studies 97.8. focussed on this hypothesis. Only one study'l found a positive association 
of sel1lm glucose levels and the mean area of dl1lsen in females without diabetes. Klein 
et al. 98 repolied no relation between glycosylated hemoglobin and ARM. Only in men 
with diabetes aged 75 years or over, a higher frequency of neovascular macular 
degeneration was found. [n the 5-year follow up study of Beaver Dam, no association 
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with incident early ARM was found, and there were not enough cases to study the 
relation with late ARM.90 The effect of hyperglycemia, if any, is likely to be small. 
Other vascular/actors 
Histopathological studies have shown that increased neutral fat deposition in Bruch's 
membrane may be related to increased senlln fatty acids and triglycerids." Many 
studies have investigated a relation between senlln lipids and ARM: some find a 
positive relation with total cholesterol and LDL,65 some find a positive relation with 
HDL, 100 but most find no relation.,,·,.·87.89.90.101 Furthermore, postmenopausal estrogens 
were shown to have a dose-related protective effect against neovascular macular 
degeneration." The role of estrogen could not be confirmed in Beaver Dam; l°'the 
power to detect an effect was low, however. The issue was also addressed in a nested 
case-control study in Rotterdam, which suggested a higher risk of AMD in women who 
had an early menopause by oophorectomy. 10) These results may be explained by the 
protective effect of estrogens against cardiovascular disease and atherosclerosis.IO'.106 
Unfortunately, the possibility of selective survival cannot be ruled out in these cross-
sectional studies. 
Environmental factors 
Smokillg 
An increased risk of ARM in smokers was first suggested by Paetkau et al. 107 The 
mechanism of the association is still unclear, but several mechanisms could playa role. 
It is plausible that, by reducing serum antioxidants,IO'·1I1 smoking decreases retinal 
antioxidants. These are present in the retina to protect it against oxygen radicals formed 
during light exposure."'·") Several other pathways could be involved in the 
association, including alteration of the choroidal blood flow. 114.'" The first reports that 
found a positive association were based on prevalent cases, 33.65.84.117.118 and not all 
findings were convincing.6).97 The association was particularly present in neovascular 
AMD, 116 but seemed to be restricted to relatively young cases. 117 Interestingly, two 
studies found that the greater the non-smoking period after cessation, the lower the risk 
for fonner smokers."7.119 Recent reports based on incident cases confirmed the strong 
associations between smoking and ARM, supporting a causal relation. Seddon et al. l2o 
evaluated the relation between cigarette smoking and any signs of incident ARM in the 
Nurses' Health study among middle-aged women with 556338 person-years of follow 
up, and found a relative risk of 2.4 (95% CI 1.4, 4.0) for those smoking over 25 
cigarettes/day. Christen et al. '21 evaluated this relation in the Physician'S Health Study 
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among men with 258115 persons-years of follow up, and found a relative risk of2.5 
(95% CI 1.6,3.9) for those smoking over 20 cigarettes/day. In the 5-year follow up 
study of Beaver Dam, Klein et al. 122 found an increased risk of incident early features 
of ARM: for men aged 43-86 years with ~ 35 pack-years of smoking, the relative risk 
of large drusen was 2.9 (95% CI 1.2,7.0), and of increased pigment 2.3 (95% CI 1.2, 
4.4). The association is impOliant since smoking is still velY common and amenable 
to prevention, and it suggests that it may be wise to advise patients with early signs of 
ARM to stop smoking. 
Alcohol 
At baseline in Beaver Dam,12J after controlling for confounding factors, consumption 
of beer was related with increased pigment (OR 1.1,95% CI 1.0, 1.25 per 105 grams 
of ethanol). In the 5-year follow up in Beaver Dam,l24 beer drinking was associated 
with soft indistinct drusen, dl1lsen confluence and increased drusen area. The lack of 
confirmation of this relation in other studies 12).126 suggests that alcohol is not likely to 
be a velY strong risk factor for ARM. 
Light e~posll/'e 
The damaging effect of light exposure on the photoreceptors and retinal pigment 
epithelium has been reported in several experimental studies.)9.6o Possibly, long-term 
exposure to light is a factor in the pathogenesis of ARM."·58 In a case-control study by 
Hyman et al. no significant association was reported between exposure to sunlight and 
ARM.JJ In a study among fishermen,6J the ocular exposure was extensively 
measured.127 No association between UV-A or UV-B exposure and ARM was 
observed. In an additional analysis based on a small number of cases, a positive 
association was observed between blue light exposure and neovascular macular 
degeneration. I" Unfortunately, the number of cases suffering from neovascular 
macular degeneration that could be included in the analysis was very small. 
Cl1Iickshanks et al. l29 reported a positive association between self-reported time spent 
outdoors in summer and the presence of dl1lsen or pigmentary changes, as well as an 
inverse association with the use of hats or sunglasses in men. Furthermore, they 
observed a positive association between leisure time outdoors in summer and 
neovascular macular degeneration. The Eye Disease Case-Control Study Group could 
not confirm an association between history of light exposure and neovascular macular 
degeneration.65 The issue was also investigated in two recent Australian studies. In the 
Blue Mountain Eye Study, llO neither histOlY of sunburns nor physical signs of 
excessive sunexposure were related to ARM. In the case-control study described by 
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Darzins et ai, sunexposure was even greater in controls than in ARM cases.131 One has 
to keep in mind that the measurement of ocular dose of light exposure is vety complex 
and susceptible to misclassification, especially with history data. A lack of an 
association could be caused by the dilution of the effect of light exposure. Moreover, 
the risk period of the exposure may be long before the development of the disease. 
Long-term follow up studies with objective measures of sun exposure at baseline are 
needed to unravel this difficult issue. 
Antioxidants and diet 
Potentially damaging effect of cumulative light exposure on the retinal layers as 
described above, raised the question whether higher blood levels of antioxidants might 
protect against ARM.61 •132 Evidence for a protective effect of antioxidant nutrients 
emerged from basic research. 13).139 A study based on the NHANES data revealed that 
a low intake of vitamin A was associated with a higher risk of ARM. 101 Newsome et 
al. suggested a beneficial effect of oral zinc on the natural course ARM. 140 The Beaver 
Dam study found a decreased risk of RPE pigmentation (OR 0.4,95% CI 0.2, 0.9) and 
RPE-degeneration (OR 0.4, 95% CI 0.1, 1.0) for subjects with a history of zinc 
supplements 10 years earlier,'41 and repeated the evidence for an association with 
hyperpigmentation in the 5-year incident study. '" Zinc has a high concentration in 
ocular tissues, serves as a cofactor for metalloenzymes such as retinol dehydrogenase, 
and may be impot1ant for the RPE by its role in protein metabolism. However, no 
protective effect of zinc was found in the Eye Disease Case-Control Study 65 or in a 
small prospective trial of zinc supplements in subjects at risk ofneovascular AMD in 
the fellow eye.l4) In the Eye Disease Case Control Study, a decreased risk of 
neovascular AMD was found for subjects with higher levels of serum cartenoids (OR 
0.4,95% CI 0.2, 0.6) 145 or for those eating cartenoid rich foods as spinach and collard 
green (OR 0.6, 95% CI 0.4, 0.9).'44 The Beaver Dam Eye Study 145 confimled a relation 
only with Iycopene, not with the cartenoids that compose macular pigment (lutein, 
zeaxanthin). One study reported that higher serum levels of a-tocopherol (vitamin E) 
were associated with a decreased risk of neovascular macular degeneration, 146 but that 
association could not be confirmed in a nested case-control study ofthe Beaver Dam,'47 
nor in the Blue Mountain.I4' In the Beaver Dam Eye Study 147 as well as in the 
Baltimore Longitudinal study of Aging 146 there was some evidence for a protective 
effect of vitamin C, but findings were inconsistent. The French POLA study recently 
showed that enzymatic antioxidant processes tilay also be involved. In a cross-sectional 
analysis among 2584 participants aged 60 years and older, this study found an 
increased risk of late ARM for subjects with high levels of plasma glutathione 
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peroxidase. 149 
The Beaver Dam Eye Study evaluated dietary fats.l47 Subjects in the highest 
quintile of saturated fat and cholesterol intake had 80% (95% CI 1.2,2.7) and 60% 
(95% CI 1.1, 2.4) increased odds of prevalent early ARM. There are no other reports 
on fat intake. 
PROGNOSIS 
Visual loss 
The risk of loss of visual acuity and the central visual field is the primary reason for 
concern about ARM. Several sttldies have shown that the disease usually affects both 
eyes of patients. 13.llO-JSl Generally, severe visual loss is caused in these patients by a 
choroidalneovascular membrane and in a smaller amount of cases by atrophy of the 
retinal pigment epithelium involving the fovea.13.ll.154 The risk of visual loss in cases 
with bilateral drusen was reported in two follow-up sttldies. Tn the first study, Gass 
reported that nine of 49 cases developed severe visual loss in one eye during an 
average follow-up period of 4.9 years.13 In the other study of 71 patients by Smiddy 
et al. l55 severe visual loss due to neovascular disease occurred in seven eyes of six 
patients. Using life-table analysis, the five-year cumulative risk of visual loss was 12.7 
percent. The interpretation of the results remains difficult, because both studies were 
based on prevalent cases with different duration of disease. l56 Furthermore, the cases 
were obtained from specialized clinics. This could have resulted in the selection of 
more severe cases, and extrapolation of the results to a general population may, 
therefore, be misleading. 
With both eyes affected, one has a severe visual handicap. The prognosis of the 
second eye in cases with unilateral neovascular AMD is, therefore, a matter of great 
concern. The issue was studied in several case_series.13.151.152,I56-160 Roy et al. 
summarized the risk of second eye involvement to be somewhere between 4 and 12 
percent annually for the first three years following the diagnosis of ARM in the first 
eye. 157 More accurate risk estimates are to be expected from cohort studies. 
Prevention of visual loss 
The need for effective treatment of AMD to prevent blindness is evident. The 
development of treatment techniques has mainly focussed on suppression of subretinal 
neovascular membranes. Effective treatment is as yet not available for drusen, 
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pigmentaty changes and atrophic AMD. For neovascular AMD, laser photocoagulation 
has been shown to effectively occlude subretinal neovascular membranes. '61 Laser 
treatment of a subretinal membrane leads to an inunediate irreversible decline of visual 
acuity when performed close to the fovea due to the destlUction of the overlying 
photo receptors, but results after two years in a smaller scar and scotoma than no 
treatment. 162 Estimations of the propOltion of patients with neovascular AMD that may 
be treated for this indication vary between 13 and 57 percent.'-'·163.IM Unfortunately, 
more than half of the treated patients suffer fi'om reCUll'enCeS of choroidal 
neovascularization within five years,'65 possibly by recanulation of the occluded 
vessels or by incomplete treatment. It is as yet inconclusive whether the new technique 
of digital indocyanine green videoangiography will be able to increase the chances of 
a favourable visual outcome by better detection of well-demarcated neovascular 
membranes. l66.l67 
Treatments under investigation 
IlIteljeroll 
Systemic interferon alfa-2 has been used to treat vascular tumors. 16'.169 It inhibits the 
growth of iris neovascularization in monkeys and even induces its regression."o In 
vitro, interferon alfa inhibits vascular endothelial cell proliferation.'" First results from 
case series172· 177 and from one small randomized trial'" suggested that interferon may 
be effective as a treatment for ARM with a slower growth of the choroidal membrane 
in neovascular AMD. However, later results from a large prospective randomized 
placebo-controlled clinical trial showed no benefit for interferon alfa-2a as a treatment 
for choroidal neovascularization."9 On the contrary, when given at a dose of 6 MIU, 
those on treatment had a poorer visual outcome after one year than those on placebo. 
Radiotherapy 
Low doses of ionizing radiation lead to regression of ocular hemangiomas ISO and of 
new vessel formation in wound healing. ISI.IS' The effect of radiotherapy on subretinal 
neovascularisation was first investigated by Chakravarthy 1S3 who reported higher 
visual acuity and smalier choroidal neovascular membranes in the treatment group after 
one year follow-up. After this study, phase IIII trials were performed which all lS4•IS ' 
but two 189.190 found a benificial effect for radiotherapy. Bergink et al. 186 was the first 
to perform a prospective randomized clinical trial that consisted of 36 subjects 
undergoing treatment and 32 subjects who did not. At 12 months follow up, 32% of 
the treatment group lost 3 or more lines of visual acuity versus 53% of the observation 
group (P=O.03). Larger randomized controlled clinical trials that study long-term 
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effects, methods and dose of irradiation, and possible side effects are currently 
underway. These results should be awaited before this treatment can be applied at 
large. 
PhotodYllamic therapy 
A large drawback of conventional laser therapy is that, due to heat conduction, the 
entire retina, RPE, and choroid surrounding the coagulation spot are irreversibly 
damaged. Photodynamic therapy is a relatively new treatment which combines laser 
with a non-thermal localized chemo-toxic reaction. The intention is to selectively 
occlude the neovascular vessels by inducing a localized photochemical process with 
low energy laser light in an area with a high concentration of photosensititizing dye. 
This dye is injected intravenously and has the property to preferentially accumulate in 
pathologic vessel proliferations. The concept of this treatment appeared promising in 
experimental treatments and animal models.!9!.!92 A recent phase IIIl clinical trial!93 
rep0l1ed the results of61 patients with classic CNV undergoing photodynamic therapy. 
All subjects showed complete cessation of leakage after I week, but leakage 
reappeared in 75% after 12 weeks, although markedly less than before treatment. 
Retreatment was effective for another Sh0l1 period,'06 and no adverse affects occurred 
below a light dose of 150 J/cm'.'07 A large phase III trial has now started to evaluate 
the long-term prognosis. 
Alltioxidallts 
If one assumes that the cumulative damaging effect of radiant energy, such as sunlight, 
on the "etinal layers is caused by the formation of free radicals, a benificial effect of 
anti-oxidants may be expected. The effect of anti-oxidant therapy is likely to be small 
but of clinical relevance.!95 Treatments with megadose vitamins E, C, fl-carotene, and 
zinc are now being investigated in the Age Related Eye Disease Study, a multicenter 
randomized trial in the USA. By design, the conclusions of this study will be limited 
to the benefits of megadose therapy in a population with an already sufficient intake 
of micronutrients. A nutricious diet seems a good recommendation, but there is not 
enough evidence at this time to advise zinc and/or antioxidant supplements.!OO Aside 
from all the potential benefits, more extensive study of the possible harmful effects is 
needed. 
Surgical intervention 
Several studies have examined the effect of surgical removal of subretinal hemorrhages 
or neovascular membranes.!97-'O' This treatment aimed at minimizing the size of the 
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scar. The indications for these techniques, however, are still a matter of debate. Most 
studies report a beneficial effect on anatomical scar size but the results fail to improve 
the functional status of the macula. Recurrence rates are likely to be as frequent as after 
laser treatment. The viability of the RPE seems to play an impOliant role as results are 
better in younger subjects. It seems reasonable to reserve these techniques for cases 
with large subretinal hemorrhages. 
Laserlherapy of early lesiolls 
Several studies are investigating whether the disappearance of dlUsen after laser 
photocoagulation has a beneficial effect on visual prognosis. The first results are 
disappointing. Preliminmy findings from the Choroidal Neovascularization Prevention 
Trial '03.204 show that significant exudative manifestations of AMD associated with the 
region oftreatment may develop after photocoagulation of soft dlUsen. 
Olher polelltial flllllre Irealmellls 
Experimental treatments that are currently under investigation are neuroprotective and 
antiangiogenic dlUgs, gene therapy, noninvasive laser targeted drug delivery, retinal 
translocation, and RPE transplantation. 
CONCLUSIONS 
ARM is a major cause of severe visual impairment in the elderly of western countries. 
The visual handicap has major consequences for the quality of life of patients and their 
relatives. In this paper we reviewed the epidemiologic findings concerning frequency, 
risk factors, and prognosis of the disease. The classification of ARM has been a matter 
of debate, but recently international agreement has been reached on the classification 
of each of the separate disease features for epidemiological studies. Although they 
established a diagnosis of the late stages, researchers still have to reach agreement on 
the classification of early stages. 
The frequency of AMD rises with age; the prevalence increases from 1% in subjects 
aged 65-74 to 10% in those over 85 years in the Netherlands. The incidence of AMD, 
expressed as 5-year cumulative incidence in the Beaver Dam Eye Study, is 1.3% in 
subjects under 75 years, and 5.4% for those aged 75 years or older. There is a clear 
need for more incidence studies of ARM, with the particular aim to confirm known 
risk factors, to specify their magnitude, and to investigate potential new factors. These 
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studies are clltl'ently taking place in North America, Europe, and Australia. 
Most known risk factors for ARM have been studied in case-control studies and 
cross-sectional population-based studies. Apart from age, genetic predisposition and 
smoking are the most definite risk factors that have been found. More extensive 
research is needed to evaluate the magnitude of the genetic component and mode of 
inheritance. Genes need to be identified, since that will lead to a better understanding 
of the underlying causes of ARM, and identification of family members at risk will 
provide the basis for future therapeutic and preventative interventions. The origin of 
the association with smoking is not fully understood yet, but the association is 
interesting since smoking habits are potentially modifiable. Other risk factors that have 
been suggested in the etiology of ARM are light exposure, atherosclerosis, and 
oxidative stress. The role of light exposure remains unclear; as yet, the possible 
harmful effect of light seems to be small. A vascular basis to the disease seems 
plausible and may provide leads for intervention. 
Patients with atrophic AMD may retain useful vision for years until the atrophy 
reaches the fovea. The prognosis in patients with neovascular AMD is generally worse. 
Further studies are needed to provide a better estimate of the prognosis. Currently, 
there is no proven treatment for the disease except for a selected group of patients with 
neovascular AMD, in which treatment with laser photocoagulation has some benefits. 
New interventions as anti-oxidant suppletion, radiotherapy, and photodynamic therapy 
are currently being investigated, and these may have beneficial consequences for 
patients who are not eligible for conventional laser treatment. Investigations to date 
certainly render encouraging perspectives, but future epidemiological studies will be 
needed to provide a better insight in course, determinants and prevention of ARM in 
the elderly. 
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Disease frequency and impact 

Chapter 
Incidence and progression of age-related 
maculopathy 
The Rotterdam Study 
Abstract 
3 
Objective: To describe the incidence of late stages of ARM and the progression of 
earlier stages, and to study the hierarchy of fundus features that detelTI1ine progression. 
Design: Population-based prospective cohort study. 
Participants: A population of 4948 subjects aged 55 years and older living in 
Rotterdam, the Netherlands, was studied to determine the incidence ofneovascular and 
atrophic AMD. A subgroup of 1244 subjects was studied for progression of early 
stages of ARM. 
Methods: At baseline and at 2-year follow-up, fundus iransparencies were graded for 
features of age-related maculopathy using the International Classification System. 
ARM was stratified in four exclusive stages according to type of dl1lsen and presence 
of pigmentary irregularities. 
Main Outcome Measures: AMD, ARM. 
Results: The overall 2-year cumulative incidence of AMD was 0.2%, increasing to 
1.2% in subjects of 85 years and older. Of the early stages, 22% showed progression 
to a more severe stage. Most imp0l1ant predictors for progression were more than 10% 
of macular area covered by drusen (OR 5.7, 95% CI 2.5, 13.1), presence of 
depigmentation (OR 5.0, 95% CI 3.2, 7.8), and hypelpigmentation (OR 3.1,95% CI 
2.0,4.7). 
Conclusions: The incidence of AMD appears to be lower in the Netherlands than in 
the United States. Progression of early stages occurs in a distinct pattern at a stable rate 
with a large area of drusen and pigmentmy changes as most important predictors. 
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INTRODUCTION 
A large number of studies have shown that ARM is a frequent eye disorder in the 
elderly,!-' and that its end stages are the most imp011ant cause of irreversible blindness 
in the Western world.'-6 The design of most of the epidemiologic studies has been 
cross-sectional, and they have provided information on disease prevalence and 
prevalence associations. In etiologic research, however, incidence is commonly 
preferred over prevalence. Incidence represents the actual disease occurrence, and risk 
analyses based on incident cases are more suggestive of a causal relation, since 
exposures are measured before the onset of disease. Incidence data of ARM would 
improve the knowledge on the etiology, early development and progression of this 
disease. At present, these data are still scarce.'·s 
The purpose of this study was to describe the incidence and progression of ARM 
in the population-based Rotterdam Study in the Netherlands. We studied the incidence 
of the late stages of ARM in the entire cohort, and investigated progression of early 
features in specific subgroups. Furthermore, we aimed to assess the prognostic value 
of the various fundus features that are associated with ARM. 
SUBJECTS AND METHODS 
Population 
The Rotterdam Study is a population-based prospective cohort study conducted in a 
suburb of Rotterdam, the Netherlands, in which chronic ophthalmologic, neurologic, 
cardiovascular, and locomotor disorders are investigated. Methods used to identify and 
describe the population have appeared in previous reports. 2•9 Baseline interview and 
screening examinations took place from 1990 to mid 1993, follow up examinations 
from mid 1993 to the end of 1994. 
Of 10,275 eligible subjects aged 55 years and older living in Rotterdam, 7983 
(78%) agreed to participate in the baseline phase of the study. Gradable fundus 
transparencies were available on 6411 subjects, of whom 104 (1.6%) subjects were 
diagnosed with the late stages of ARM, i.e., atrophic or neovascular AMD. This 
resulted in a cohort of 6307 subjects at risk for incident AMD. 
Procedures and definitions 
The screening for presence of ARM followed the same protocol at baseline and at 
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follow up. Procedures have been described in detail elsewhere.'" In brief, during the 
screening eye examination color transparencies centered on the macula were taken with 
a monoscopic (35° field; Topcon TRY-50YT fundus camera, Topcon Optical 
Company, Tokyo, Japan) and stereoscopic camera (200field; Topcon TRY-SS2 fundus 
camera, Topcon Optical Company, Tokyo, Japan). The diagnosis of ARM features was 
based on grading of fundus transparencies according to the International Classification 
System,1O in which all features of age-related maculopathy are called ARM and the two 
late stages are called AMD. At baseline, fundus transparencies of the entire cohort 
were graded in a detailed manner to identify all features of ARM present in the 
macular grid area (radius, 30001"'11). At follow up, all fundus transparencies of the 
entire cohort were graded for presence of atrophic or neovascular AMD, Inter- and 
intra-rater agreement on all fundus features was checked every 1000 subjects, and 
consensus training was performed when weighted kappa values fel below 0.6. 
Table 1. Stratification of ARM in exclusive stages of severity 
Stage of Criteria 
No, No, No. selected 
ARM at baseline at follow~up for analysis 
No ARM No ARM fcatures or only 
drusen 5: 63 ~lIn 4025 3234 327 
Stage I (i) Soft distinct drusen 
1465 1144 331 
(ii) Pigmentary irregularities 
332 248 248 
without soft drusen 
Stage 2 (i) Soft indistinct drusen or 
121 
reticular dnlsen 180 121 
(ii) Soft distinct dnlsen with 
170 pigmentary irregularities 222 170 
Stage 3 Soft indistinct or reticular dl1lsen 
with pigmentary irregularities 83 47 47 
Stage 4 Atrophic or neovascular macular 
104 54 0 degeneration (AMD) 
To assess the incidence and progression of early ARM features, ARM at baseline 
was stratified in four exclusive stages of disease (Table I). On the basis of previous 
findings",8,11.12 we assumed more clinical severity and a higher risk of development of 
AMD with each successive stage. The stage classification of a subject was based on 
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the eye with the most severe stage of ARM. ARM stages I (i) and (ii) were considered 
one stage of clinical severity, as were stages 2 (i) and (ii). For reasons of feasibility and 
efficiency, only a randomly selected subset of subjects with no ARM or ARM stage 
I (i) at baseline underwent detailed grading of early ARM features at follow up. Of all 
other stages, the entire group of subjects with grad able fundus transparencies 
underwent detailed grading at follow up. 
Incidence of an ARM lesion was defined as absence of this particular lesion within 
the grid area of either eye at baseline and presence of this lesion in at least one eye at 
follow up. Progression of ARM was defined as an increase in one or more stages of 
ARM; no progression was defined as no change or a decrease in stage. 
Statistical methods 
Subjects with AMD at baseline were excluded from the incidence and progression 
analyses. The age-specific incidence of AMD was obtained per I O-year age-categories 
by dividing the number of incident cases by the number of person-years per age-
category. The latter was calculated by summing each pmiicipant's contribution of 
follow up time per age-categOly. Confidence intervals of incidence rates were 
calculated with the exact method. Age at follow up was regarded as age at onset of 
incident AMD. Cumulative incidences were calculated from the incidence rates with 
the formula 
- IR*t 
CI (I) = 1- e 
where CI is the cumulative incidence over a period of t years, IR is the incidence rate, 
and e is the constant 2.71828, the base of the natural logarithm. 
Progression of early ARM stages was studied by logistic regression analysis with 
age, gender, baseline stage of ARM and duration of the follow up period fixed in the 
model. In an initial 'univariate' analysis with these fixed factors the predictive power 
of drusen size and location, proportion of macular grid area covered by drusen, most 
frequent drusen size, largest drusen size, drusen confluence, presence and ~rea of 
hypelpigmentation, and presence and area of depigmentation was evaluated. Statistical 
interaction between macular area of drusen and hyper- or depigmentation, between 
hyper- and depigmentation, and between area of dnlsen and drusen confluence was 
studied by entering the product term of these factors in the model. Fundus features or 
product temlS with a significant odds ratio entered a subsequent 'multivariate' analysis 
to determine the independence and magnitUde of prognostic factors. 
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RESULTS 
Incidence of AMD 
Of the 6307 subjects at risk for incident AMD, 5442 (86%) participated in the 2-year 
follow up phase of the Rotterdam Study. Of the non-participants, 326 subjects had died 
before follow up, and 539 (10%) subjects refused to participate in any follow up 
examination. Of subjects that consented to follow up, 5097 participated in the re-
screening eye examination. Gradable fundus transparencies of at least one eye were 
present in 4948 subjects, 78% (4948/6307) of the total number of subjects at risk for 
incident AMD, and these subjects were included in the incidence analyses. They 
significantly differed from other eligibles by age, but, after adjustment for age, not by 
stage of ARM at baseline (table 2). 
Table 2. Baseline characteristics of subjects at risk of incident AMD 
ElIgibte subjects (u~6307) 
, Characteristics In analysist Not in al1alysis~ (n~4948) (n~1359) 
Age at baseline (%) 
55 - 64 Y 43.2 24.3 
65 - 74 Y 38.t 30.2 
75 - 84 Y t6.2 33.0 
85 + Y 2.5 t2.5 
Gender (% women)§ 58.5 6t.3 
Institutionalized (%)§ 4.4 10.2 
ARM at baseline (%)1 
Stage t 29.t 28.4 
Stage 2 6.5 5.9 
Siage 3 t.t 2.t 
I subjects with gradable fundus transparencies 
I deceased, non-participants, and subjects with ungradable fundus transparencies 
t adjusted for age 
p 
<O.OOt 
0.07 
<O.OOt 
0.t5 
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After an average follow up period of 2.0 (SO 0.6) years, II cases were identified 
with incident AMO. Of those, 5 cases were identified with atrophic AMD and 6 with 
neovascular AMD. Given a total of 9833 person-years, the overall incidence of AMD 
was 1.1 per 1000 person-years (2-yr cumulative incidence 0.22%). The incidence 
increased with age (table 3). Figure I shows the estimated 5-year cumulative incidence 
risk in the Rotterdam Study in comparison with the two other population-based 
incidence studies that report 5-year incidences. 
Table 3, Age-specific incidence rates per 1000 person-years and 2-year cumulative 
incideuces (%) of AMD in the Rotterdam Study 
Age-group Person-years N Rate 95% CI 2-yr incidence 
55·64 3530 o 0 (0,0.001) 0 
65-74 4009 0.2 (0.01,1.4) 0.05 
75·84 1955 8 4.1 (1.8,8.1) 0.82 
85+ 338 2 5.9 (0.7,21.4) 1.18 
Total 9833 II 1.1 (0.6,2.0) 0.22 
Overall, there were no statistically significant gender differences in incidence of 
AMD. Among the 2078 men, the overall incidence was 1.00 per 1000 person-years (2-
yr cumulative incidence 0.2%), while among the 2870 women, the overall incidence 
was 1.20 per 1000 person-years (2-yr incidence 0.2%, P = 0.24, adjusted for age and 
follow up time). 
Incident AMD was strongly associated with stage of ARM at baseline. Neither 
ARM stage 0 nor stage I progressed to incident AMD. ARM stage 2 gave rise to 3 
subjects with incident atrophic AMD and 4 with incident neovascular AMD. For this 
stage, the overall incidence rate of AMD was 12.1 per 1000 person-years (2-year 
cumulative incidence 2.4%), ranging from 4.0 per 1000 person years (2-yr incidence 
0.8%) in subjects under 65 years to 35.4 per 1000 person-years (2-yr incidence 6.8%) 
in subjects aged 85 years and older. Stage 3 at baseline gave rise to 2 subjects with 
incident atrophic AMD and 2 with incident neovascular AMD. For stage 3, the total 
incidence rate of AMD was 38.6 per 1000 person-years (2-yr incidence 7.4%), and the 
age-category in which this occurred was 74-85 years. 
Of the 31 subjects with AMD in only one eye at baseline, 3 subjects with atrophic 
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AMD and 4 subjects with neovascular AMD developed incident AMD in the second 
eye at 2-yr follow up. This resulted in an incidence rate of 109.9 per 1000 person-years 
(2-yr cumulative incidence 19.7%) for involvement of the second eye. The 3 subjects 
with unilateral atrophic AMD at baseline developed the same type of AMD in the 
second eye. Of the 4 subjects with neovascular AMD, 2 developed neovascular AMD 
and 2 developed atrophic AMD in the other eye. The baseline ARM stages of the 
second eye were stage 2 (3 subjects) and stage 3 (4 subjects). 
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Progression of early stages 
Of the 1244 subjects who were selected for the early ARM progression analyses, 315 
subjects progressed to a more severe stage of ARM. For the total cohort, this implied 
a 2-year cumulative progression rate of 21.5%. Table 4 shows the incidence rates of 
the various stages of ARM at follow up. Age was associated with progression: adjusted 
for gender, follow up time and baseline stage of ARM, the odds ratio of progression 
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for age per year was 1.02 (95% CI 1.00, 1.03). Gender was not associated with 
progression; the odds ratio for women versus men was 0.98 (95% CI 0.75, 1.27; 
adjusted for age, follow up time and baseline stage of ARM). 
Table 4. Incidence rates of the various stages of ARM per 1000 person-years 
based on 2-year follow-up (2-yr cUlllulative incidences,%) 
Stage of ARM Follow-up Follow-tip Follow-up Follow-up Stage 1 Stage 2 Stage 3 Stage 4 
Baseline Stage 0 112.8 (20%) 4.5 (1%) 0 0 
Baseline Stage I 112.5 (20%) 15.8 (3%) 0 
Baseline Stage 2 119.9 (21%) 11.7 (2%) 
Baseline Stage 3 37.6 (7%) 
In the 'univariate' analysis of prognostic factors, macular a"ea covered by drusen, 
presence and area of hyper pigmentation, presence and area of depigmentation, number 
of small drusen (~ 63,um), number oflarge dnlsen (~125,um), and drusen confluence 
were significantly associated with progression (data not shown). In the 'multivariate' 
analysis with these significant factors in the model, all factors except number of large 
drusen (~125,um) remained statistically significant. A large area of drusen was the 
most important predictor of ARM progression; the odds ratio for> 1 0% of macular area 
covered by drusen was 5.8 (95% CI 2.5, 13.3) (table 5). The other impo.iant 
independent predictors were presence of depigmentation, hyperpigmentation, 10 or 
more small drusen, and at least 10% drusen confluence. Area of depigmentation with 
a total diameter larger than 500 ,um had a higher odds ratio than did smaller area's 
(odds ratio for area >500,um versus area <175 ,um4.61 (95% CI 2.48, 8.56), indicating 
that larger area's of depigmentation Were more prognostic than smaller area's. Area's 
of hyper pigmentation larger than 125,um did not have higher odds ratio's than area's 
of 125,um or smaller, indicating that larger area's of hyper pigmentation were not of 
additional prognostic value. We found no evidence for statistical interaction between 
area of drusen and pigmentmy irregularities, between hyper- and depigmentation, or 
between area and confluence of dl1lsen (data not shown). 
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Table 5. Fundus features prognostic for progression of ARM 
Fundus feature 
Total drusen area::: 10% of grid 
Presence of depigmentation 
Presence of hyperpigmentation 
;dO small dmsen (..,;.63)..tm) 
::: 10% drusen confluence 
OR (95% CI)' 
5.78 (2.52.13.30) 
4.95 (3.15. 7.79) 
3.09 (2.02, 4.72) 
3.01 (1.90,5.11) 
2.77 (1.81, 4.24) 
• based on a model which included these factors, plus age, baseline stage of ARM, and 
duration of follow~up period 
DISCUSSION 
In the Rotterdam Study, the incidence of ARM's late stage, AMD, was 1.12 per 1000 
persons per year for subjects aged 55 years and over. The incidence of AMD showed 
a strong relation with age and increased to 5.9 per 1000 persons per year for those aged 
85 years and older, which appeared to be lower than in the United States. The 
incidence of AMD in the contralateral eye of subjects already affected by unilateral 
AMD was 109.9 per 1000 persons per year. The most predictive stage for development 
of incident AMD was ARM stage 3, which comprises the presence of either soft 
indistinct or reticular dt1lsen, or soft dt1lsen with pigmentmy irregularities. Progression 
of early stages of ARM occurred in a very distinct pattern at a rate of 22% in two 
years. Most important predictors for progression were more than 10% of macular area 
covered by drusen, presence of depigmentation, and presence of hyperpigmentation. 
A good estimate of the incidence of AMD requires the follow up of many subjects 
over a long period of time, because the occurrence of this clinical end stage is 
relatively infrequent. A large study population with a significant number of elderly is 
one of the strengths of the Rotterdam Study. However, the length of the follow up 
period was limited, and the number of subjects who developed incident AMD was low. 
Therefore, our estimated incidence rate of AMD is rather imprecise. On the other hand, 
the shott follow up period was a benefit for the study of the progression of early ARM 
stages. This enabled us to register small changes and to determine a pattern of 
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progression, which may add to the understanding of the natural course of this disease. 
Lost to follow up is a concern in this study, as it is in all cohort studies. Non-
participation at the second round was mainly due to mortality and non-response to the 
entire study, not to the eye examination itself. Comparison of subjects in the analysis 
with subjects that were not, showed that the latter group was older, but the groups did 
not significantly differ in stage of ARM at baseline. Thus, the effect of lost to follow 
up on our findings may be limited. 
The age-specific incidences of AMD appeared to be lower in the Rotterdam Study 
than in the Waterman Study or the Beaver Dam Eye Study (figure I)Y The American 
studies took place in different parts of the United States, but show incidences within 
the same range. We estimated a five-year cumulative incidence by extrapolation ofoUl' 
data in order to allow for a meaningful comparison, and in coming years we will be 
able to evaluate whether this estimation is correct. Nevertheless, the difference seems 
considerable, consistent over the age-groups, and in agreement with earlier reports 
indicating global differences in the occurrence of AMD. Comparison of prevalence 
data from the Beaver Dam Eye Study, the Blue Mountain Eye Study, and the 
Rotterdam Study showed that the prevalence of AMD was highest in the United States 
and lowest in the Netheriands. I.' The three studies used vety similar methods of 
diagnosis based on fundus photography, which makes it less likely that the differences 
were a result of observation bias. Known risk factors such as smoking and 
cardiovascular disease did not explain the differences ("Smith et ai, submitted"), and 
it remains a key point of interest to identify the environmental and genetic factors that 
are accountable. 
The 2-year incidence of AMD in the fellow eye in subjects with unilateral AMD 
was 20%, and the type of AMD was not necessarily concordant with the first eye. The 
Beaver Dam Eye Study found a 5-year incidence of 22% for the second eye,' 
considerably lower than the Rotterdam Study. The lower age-range in -Beaver Dam 
may well account for this difference. Our data are in line with clinic-based studies 
reporting the rate of fellow eye involvement. The majority of these studies focussed 
on patients with neovascular AMD, and estimates for annual second eye incidence 
mostly ranged from 4 to 10%,11.13.17 although annual incidences up to 15% have been 
published. 18 Comparison of rates is generally hampered by differences in age, duration 
of disease, and diagnosis, and long-time follow up oflarge, well-defined study groups 
will be needed to provide valid and precise estimates. 
An important objective of the study was to describe the progression of early 
features of ARM. For long it has been known that soft drusen and pigmentary changes 
are precursor lesions that increase the risk of geographic atrophy and neovascular 
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AMDY·II-20 After appearing, dl1lsen and pigmentmy changes may regress and 
disappear, but generally this is a result of appearance of more severe lesions.'·s In the 
Rotterdam Study, we did not focus on individual fundus lesions. To enhance clinical 
relevance, we preferred to study progression of ARM in exclusive stages of disease. 
We stratified early features of ARM in three stages based on type of dl1lsen and 
presence of pigmentmy changes, the factors which have been shown to be strong 
predictors for the development of AMDY·" ·'2 The ranking of the stages was in 
accordance with clinical severity: the risk of AMD increased from vhtually no risk for 
stages 0 and I, to a 2-year risk of 2.4% and 7.4% for stages 2 and 3, respectively. An 
interesting finding was that progression predominantly occurred to only one more 
advanced stage at a rate of approximately 20% in 2 years for the earliest stages (table 
4). Progression from stage 3 to 4 was slower and occurred at a rate of7% in 2 years. 
Some subjects progressed fast and skipped one stage, but no subjects skipped more 
than one stage in the 2 years of follow up. Although future studies are awaited to 
confirm these data, our findings add to the view that development of ARM is not a 
random occurrence of events, but rather seems to follow a well-defined pattern at a 
stable rate. 
In accordance with others,' we found that a large area of the macula covered by 
dl1lsen and pigmentaty irregularities were impOttant and independent predictors of 
ARM progression. Other predictors were number of small dl1lsen, and dl1lsen 
confluence. The number of intermediate (64-1 24ftm) and large drusen (z 1 25f1m) did 
not have additional predictive power, neither did location of dl'Usen. Although small 
dl1lsen (,,; 63f1m) are not considered an ARM feature in the intemational Classification 
System, our data indicate that more than 10 small drusen are predictive of ARM 
progression independent of other features. This is consistent with findings from the 
Waterman Study' and the Beaver Dam Eye Study,' which both reported that many 
small dl1lsen increased the risk of large and soft indistinct dmsen, but not of AMD. 
From our results and those of others we conclude that progression of early ARM 
appears to follow a distinct pattern. A large number of small hard dl1lsen or isolated 
pigmentary changes may indicate the vety early start of ARM. Then soft dl1lsen 
emerge. Subsequently, at a stable rate, multiple drusen of various sizes appear and 
become confluent, the total area increases and some of the dntsen become soft 
indistinct. The appearance of pigmentmy changes at this stage, especially large areas 
of depigmentation, then further increases the risk of AMD. Subretinal 
neovascularization or development of geographic atrophy denote the etiologic end 
stage of ARM. 
In conclusion, the 2-year incidence of AMD in the Rotterdam Study was 2.2 per 
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1000 sUbjects. Our data provide further evidence that ARM is a progressive disease 
with a distinct temporal sequence of events ultimately ending in AMD. 
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Age-specific prevalence and causes of blindness 
and visual impairment in an older population 
The Rotterdam Study 
Abstract 
Objectives: To study the prevalence and causes of blindness and visual impairment 
in various age categories of a large population-based study. 
Methods: For the study, 6775 subjects aged 55 years and older underwent an extensive 
ophthalmological screening examination, including measurements of visual acuity and 
the visual field, and fillldus photography. The causes of blindness or visual impairment 
were determined using all screening information and medical records. 
Results: The prevalence of blindness, according to WHO criteria, ranged from 0.1 % 
in subjects aged 55-64 years to 3.9% in subjects aged 85 or older; the prevalence of 
visual impairment ranged from 0.1 % to 11.8%. For persons younger than 75 years, 
myopic degeneration and optic neuropathy were the most important causes of impaired 
vision. For persons aged 75 years or older, AMD was the major cause of the increased 
prevalence of blindness, whereas age-related cataract predominantly caused the 
increased prevalence of visual impairment. 
Conclusions: The hierarchy of causes of blindness and visual impairment is highly 
determined by age. As yet, little can be done to reduce the exponential increase of 
blindness; however, adequate implementation of surgelY to treat cataract could reduce 
visual impairment by one third. Underuse of ophthalmological care is a prominent 
cause of the high frequency of untreated cataracts among the elderly. 
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INTRODUCTION 
Blindness is the functional end stage of many eye disorders. The occurrence and course 
of these disorders differ markedly throughout the world, and this is reflected by 
differences in the prevalence of blindness and visual impairment.' International 
comparison of these data may help to provide insight in the risk factors associated with 
blinding eye disorders, and facilitate evaluation of therapeutic modalities and 
prevention programs. 
Various population-based studies have provided precise estimates on prevalence 
and incidence of blindness and visual impairment in Western countries."" All show 
a clinically significant increase in the prevalence of impaired vision with increasing 
age. To fully understand this increase, to make a meaningful comparison between 
countries, and to develop efficacious strategies for eye care for a wide spectmm of 
ages, accurate data on the age-specific causes of impaired vision are essential. Few 
such data exist, however. 
The Rotterdam Study is a population-based study of the occurrence and 
determinants of various disorders in a middle-aged and elderly population. The age 
range is wide in this study, and the proportion of 80- and 90-year-old subjects 
substantial. In the present study, we analyzed data from the Rotterdam Study to 
describe the age-specific prevalence and causes of blindness and visual impairment in 
an older, predominantly white Western population. 
SUBJECTS AND METHODS 
Subjects 
The rationale and design of the Rotterdam Study have been described elsewhere." In 
brief, this population-based prospective follow-up study focuses on chronic 
ophthalmologic, neurologic, cardiovascular and locomotor diseases among subjects 
aged 55 years or older living in Onunoord, a city district of Rotterdam. Baseline data 
were collected between 1990 and 1993. Eligibles were identified by drawing names 
and addresses from the municipal register. During an initial home interview, 
demographic characteristics, medical and ophthalmological history, the use of eye care, 
attained level of education, the level of ability in daily activities, and a variety of other 
variables were evaluated. Subsequently, pmiicipants underwent a physical examination 
at the screening center. Subjects living in the six nursing homes ofthe target area were 
examined at their homes. 
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Procedures and definitions 
The ophthalmological examination included measurements of visual acuity, ocular 
refraction, visual fields, and intraocular pressure; slitlamp examination; and direct and 
indirect ophthalmoscopy. The examination was performed by two ophthalmologic ally 
trained physicians who determined the presence of cornea and lens opacities, and 
vitreous and fundus changes using a standardized grading protocol. In addition, 20° 
stereoscopic fundus color transparencies were taken of the optic disc (Topcon TRC-
SS2 stereoscopic fundus camera, Topcon Optical Company, Tokyo, Japan), and 35 ° 
color transparencies were taken of the macular area (Topcon TRV-50VT fundus 
camera, Topcon Optical Company, Tokyo, Japan). Visual acuity was measured at a 3 
m distance using the Lighthouse Distance Visual Acuity Test, a modified Earley 
Treatment Diabetic Retinopathy Study chart.!2 To evaluate best-corrected visual acuity, 
optimal refraction was obtained subjectively after objective autorefraction. Screening 
of visual fields was perfol1ned using a modified 76-point supra-threshold perimetlY test 
(Humprey Visual Field Analyzer, Zeiss, Oberkochen, Germany); visual field defects 
were subsequently confirmed by using Goldmann perimetty. 
The various population-based studies evaluating blindness have used different 
criteria for blindness and visual impairment. We used two sets ofcritel'ia for blindness 
and visual impairment to enable comparison of our prevalence data with others. The 
first set of criteria was established by the World Health Organization and used in the 
International Classification of Diseases; blindness is defined as a best-corrected visual 
acuity of less than 0.05 (Snellen, 20/400) in the better eye or a visual field no greater 
than 10° around central fixation; and visual impailment, as a best-corrected visual 
acuity of less than 0.3 (20/60) but no less than 0.05 (20/400) in the better eye.lJ The 
second set of criteria is used most commonly in the United States; blindness is defined 
as a best-corrected visual acuity of 0.1 (20/200) or less in the better eye, and visual 
impairment as a best-corrected visual acuity less than 0.5 (20/40) but better than 0.1 
(201200) in the better eye. The cause of visual loss was determined for blindness and 
visual impairment according to the WHO criteria. Two clinical investigators 
(C.C.W.K. and P.T.V.M.J.) reached consensus on the final determination ofthe cause 
of visual loss after reviewing all screening information, fundus transparencies, and, 
when necessary, information provided by ophthalmologists. Standard procedures and 
standard clinical criteria were applied. In most cases, the cause of visual loss was a 
single disorder. When multiple disorders were present, we attempted to identify the 
disorder causing the greatest limitation of vision. In a few subjects, no primaty cause 
of the visual loss could be identified, and visual loss was considered due to a 
combination of mechanisms. 
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To evaluate the presence of diabetes mellitus, a non-fasting oral glucose tolerance 
test was performed for all subjects not using antidiabetic medication. Diabetes mellitus 
was defined as the use of antidiabetic medication or a random or postload glucose level 
greater than II nUlloVL (198mgldL). A screening test for cognitive function comprised 
the Mini-Mental State Examination; a low score indicates poor cognitive function." 
The attained level of education was evaluated according to the standard classification 
of education," which is comparable to the international standard classification of 
education (UNESCO, Paris, France, 1976). Four levels of education were included, the 
lowest was primaty education and the highest university or higher vocational 
education. Ability in daily activities was measured in eight components (ie, dressing, 
rising, reach, hygiene, eating, walking, grip, and activity) as described previously."·l7 
Moderate disability was present when subjects had difficulties in four out of eight 
components. 
Data analysis 
The prevalences of blindness and visual impairment were calculated as percentages of 
the total study population and stratified by age and gender. The prevalences of causes 
of blindness and visual impairment were calculated as percentages of affected eyes in 
three age-categories. The prop0l1ions of categorical variables and the differences in the 
categorical variables between groups were calculated by using multiple logistic 
regression analysis with adjustment for age and gender; means and differences between 
continuous variables were adjusted by using analysis of covariance. The SlltH of the 
age-specific prevalences of blindness and visual impairment was calculated to 
represent the total prevalence of poor vision (i.e., blindness and visual impairment). 
RESULTS 
A total of 10 275 eligible subjects were identified during recrnitment, and 7983 
(77.7%) consented to an initial home interview. Of these subjects, 6775 participated 
in the ophthalmologic examination. On the basis of other available data, differences 
in general characteristics between subjects who underwent the ophthalmologic 
examination and subjects who did not could be evaluated. Compared with participants 
in the ophthalmologic examination, nonparticipants were significantly older, were 
more often women and were more often institutionalized; nonparticipants had lower 
scores on the Mini Mental State Examination, and were more likely to have visual and 
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other health problems. The use of anti-diabetic medication was not higher among 
nonparticipants. 
By using the WHO-criteria, we identified 32 subjects who were blind and 96 
subjects who were visually impaired in both eyes. Table I gives the more specific 
distribution of characteristics among these subjects compared with subjects with better 
vision. Compared with subjects with better vision, subjects who were blind or visually 
impaired were significantly older (Student t test; P<O.OO I). After adjustment for age, 
they were stillmore likely to be institutionalized (21 % vs 9%; P<O.OO I), showed more 
disability in daily activities (41 % vs 33% P<O.OO I ),and had slightly lower scores on 
the Mini Mental State Examination (25.0 vs 27.2; P<O.OO I). There were no significant 
differences in presence of diabetes mellitus (12% vs II %; P=O.l) . 
Table 1. General and clinical characteristics . 
Blind Visu~lly impail'ed Subjects with 
subjects subjects visual acuity ~ 0.3 
(n~32l (1l~96l (n~6647) 
Age 83+ 84+ 69 
Women (%) 75 71t 59 
Instihltionalized (%) 451 28+ 7 
Homebound (%) 30+ 2q 6 
Moderately disabled (%) 52t 47+ 30 
Mini~Mental State Examination score 25.q 26.1+ 27.3 
Level of education (%) Lowest 36 42 38 
Highest to 8 9 
Diabetes mellitus (%) 12 6 tl 
Visited ophthalmologist for other 
771 59t 41 
reason than to obtain glasses (%) 
• Values are means, adjusted for age and gender, unless othenvise indicated. 
I P<O.05 for the difference with subjects with visual acuity ~O.3 (Snellen, 20/60) 
I P<O.OOI for the difference with subjects with visual acuity ;:..0,3 (Snellen, 20/60) 
The prevalence of blindness and visual impairment stratified by age and gender is 
given in Table 2. Whatever criteria were used, blindness and visual impairment showed 
a significant increase in prevalence in subjects aged 75 years or older. Women had 
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slightly higher prevalences of blindness or visual impairment in most age strata, 
although the differences were not statistically significant after additional adjustment 
for age within the age strata. Figure 1 shows a comparison of our data with prevalence 
data from other studies based on white populations. Compared with the results of other 
studies, the prevalence of blindness and visual impairment in the Rotterdam Study was 
low for all groups older than 55 years, although the Rotterdam Study did not have the 
lowest prevalence at evelY age point. 
Table 2. Prevalence of blindness and visual impairment according to WHO and 
US criteria, stratified by age and gender' 
Blindness Visual impnirmeut 
Age (yrs) Tafalno. WHO US WHO US 
Men % Percentage of study subjects (n) 
55·64 1097 0.1 (I) 0.1 (I) 0.1 (I) 0.3 (3) 
65· 74 1054 0.2 (2) 0.2 (2) 0.1 (I) 0.7 (7) 
75·84 504 0.4 (2) 1.0 (5) 2.2 (II) 6.0 (30) 
> 85 89 I.l (I) 3.4 (3) 9.0 (8) 28.1 (25) 
Total 2744 0.2 (6) 0.4(11) 0.8(21) 2.4 (65) 
Women 
55-64 1464 0.1 (2) 0.2 (3) 0.1 (2) 0.5 (7) 
65-74 1354 0.1 (2) 0.1 (2) 0.6 (8) 1.0 (13) 
75-84 894 0.8 (7) 1.6 (14) 2.8 (25) 8.5 (76) 
> 85 319 4.7 (15) 6.6(21) 12.5 (40) 30.4 (97) 
Total 4031 0.6 (26) 1.0 (40) 1.9 (75) 4.8 (193) 
• WHO indicates World Health Organization. Data are given as percentage (number) of study subjects. 
In most subjects, the cause of visual loss was the same for both eyes. However, in 
3 (9%) of the 32 blind subjects and in 18 (19%) of the 96 visually impaired subjects, 
the two eyes had different causes of visual loss. For this reason, the prevalences of the 
various causes of visual loss are most clearly presented as percentages of eyes rather 
than percentages of sUbjects. Table 3 gives the causes of blindness for three age 
categories. Optic neuropathy was the most frequent cause of blindness for subjects 
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aged 55 to 74 years. In subjects aged 75 years or older, age-related macular 
degeneration became the most impOliant cause of blindness and was most apparent in 
the oldest age category. PrimalY open-angle glaucoma and cataract were second and 
third most important causes of blindness, respectively. In the two cases of combined 
mechanisms, we could not detelTIline which disorder limited vision the most, myopic 
macular degeneration or primaty open-angle glaucoma. The rare causes included 
pigment dispersion syndrome with secondaty glaucoma, congenital syphilis, and 
atrophy of the eyeballs as a complication of surgely to correct a retinal detachment 
Table 3. Causes of blindness in 64 eyes of 32 blind subjects, stratified by age' 
55-74 )'I'S 75-84 )'rs ~ 85 yrs All Cause (14 eves) (18 eves) (32 eres) (64 eves) 
Age~related macular degeneration 14 (2) 56 (10) 78 (25) 58 (37) 
Cataract 0(0) II (2) 6 (2) 6 (4) 
Primary open angle glaucoma 14 (2) 0(0) 9 (3) 8 (5) 
Myopic degeneration 14 (2) 0(0) 6 (2) 6 (4) 
Optic neuropathy 29 (4) 0(0) 0(0) 6 (4) 
Retinitis pigmentosa 14 (2) 0(0) 0(0) 3 (2) 
Rare causes 14 (2) 22 (4) 0(0) 9 (6) 
Combined mechanisms 0(0) II (2) 0(0) 3 (2) 
• Blindness according 10 WHO-classification: best-corrected visual acuity < 0,05 (Snellen, 20/40) in the better eye. 
Data are given as percentage (number) of eyes. 
The causes of visual impairment according to WHO criteria are listed in Table 4. 
Myopic macular degeneration was the predominant cause of visual impairment in 
subjects younger than 75 years. For subjects aged 75 years or older, cataract, as a 
single cause or in combination with other disorders, became the leading contributor 
to visual impairment. In 62 (65%) ofthe 96 visually impaired subjects aged 85 years 
or older, cataract contributed at least partially to the visual impairment. The disorder 
most frequently accompanying cataract as a cause of impaired vision was age-related 
macular degeneration, followed by primary open-angle glaucoma. The combined 
mechanisms included corneal dystrophy with macular hole, myopic macular 
degeneration with optic neuropathy, and age-related macular degeneration with 
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primaty open-angle glaucoma. The rare causes comprised hereditary macular 
degeneration, neuroretinitis, enucleation of the eyeball after complications of 
combined surgelY to treat glaucoma and cataract, retinopathy without a known cause, 
and venous branch occlusion. 
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Figure 2 shows, by age, the proportions of poor vision (blindness and visual 
impairment, WHO-criteria) caused by age-related macular degeneration, age-related 
cataract and primaty open-angle glaucoma. As single causes, these 3 disorders 
comprised the largest part of the increase in the prevalence of poor vision; 
combinations of these disorders and other single causes increased the prevalence of 
impaired vision only moderately with age. 
Of the three major causes, age-related cataract is the only cause for which treatment 
may be sufficiently successful to restore vision. Cataract-extraction was a common 
surgical procedure in our study popUlation of6775 subject; its overall prevalence was 
5.5% (371 subjects), ranging from 1.4% (35 subjects) in persons aged 55 to 65 years 
to 21.3% (87 subjects) in persons aged 85 years or older. Cataract extraction had 
prevented or treated possible bilateral blindness and visual impairment (as bilateral 
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cataract extraction or unilateral extraction with blindness or visual impairment in the 
other eye) in 3.6% (234 subjects) of the total study population and up to 15.2% (62 
subjects) of persons aged 85 years or older. Of interest is that more than half(53%) of 
the subjects who were blind or visually impaired owning to untreated cataract 
indicated that they had never visited an ophthalmologist. To identify possible reasons 
for not seeking appropriate care, we compared the variables listed in Table I between 
subjects who were bilaterally blind or visually impaired due solely by cataract (IF34) 
and subjects who had undergone surgery to treat cataract (n=371). Compared with 
subjects who had undergone surgelY to treat cataract, blindness or visual impairment 
due to untreated cataract was associated with a higher proportion of subjects over 85 
years (21 % vs 58%, respectively, P<O.OO I), being homebound owing to health reasons 
(17% vs 33%, respectively, age-adjusted, P=0.03), and a higher proportion of low 
scores (~20) on the Mini Mental State Examination (6% vs 20%, respectively, age-
adjusted, P=0.004). Differences in gender and level of education were not statistically 
significant; however, none of the subjects with untreated cataract had attained 
university or higher vocational education. 
Table 4. Causes of visual impairment in 192 eyes of 96 visually impaired subjects, 
stratified by age* 
Calise 55-74 )'1' 75-84 )'1' > 85)'1' All 
Age-related macular degeneration 5 (I) 28 (21) 27 (26) 25 (48) 
Cataract 18 (4) 35 (26) 42 (40) 36 (70) 
Cataract in combination with another calise t8 (4) 12 (9) 23 (22) t 8 (35) 
Primary open angle glaucoma 0(0) 3 (2) t (I) 2 (3) 
Myopic macular degeneration 23 (5) 4 (3) 3 (3) 6 (II) 
Optic neuropathy 9 (2) 0(0) 0(0) t (2) 
Comeal dystrophy 9 (2) I (t) 0(0) 2 (3) 
Diabetic retinopathy 9 (2) 0(0) 0(0) 1 (2) 
Rare causes 9 (2) 11 (8) 3 (3) 6 (13) 
Combined mechanisms 0(0) 5 (4) 1 (I) 3 (5) 
• Visual impainnenl according to WHO-classification; best-corrected visual acuity ?:O,05 (Snellen, 20140) and <0.3 
(Snellen, 20/60) in the better eye. Data are given as percentage (number) of eyes. 
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DISCUSSION 
We have presented age-specific prevalences and causes of blindness and visual 
impairment in a population ranging in age from 55 to 106 years. Our data indicate that 
AMD is the main contributor to the exponential increase in the prevalence of blindness 
in persons aged 75 years or older and that age-related cataract causes the major 
increase of visual impairment. Myopic macular degeneration, optic neuropathy, and 
various other less frequent disorders have important contributions to the poor vision 
occurring before the age of75 years. 
FigUl'e 2. Total pl'walellce of pOOl' visioll (blilldlless alld vis/wi impail'mellt 
accol'dillg to WHO-criteria) as a fllllctioll of age, specified by calise. AMD illdicates 
age-relatell macular degelleratioll; POA G, primary open-allgle glaucoma 
All population-based studies during the 1990s on the prevalence of blindness and 
visual impairment show an exponential increase with age.'-IO However, the age-
specific prevalences Vaty considerably among studies (figure I). Although the 
variations may be due to study design, population sampling, or differences in 
measuring techniques, they may indicate real geographic variation in prevalence and 
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course of vision-impairing disorders. This points out a need for detailed information 
on the age-specific causes of impaired vision. 
The size of our study enables relatively precise estimates of the prevalence of 
blindness and visual impairment and facilitates an accurate determination of the 
proportions of causes. Our population was predominantly white, and because black 
populations are known to have higher prevalence of poor vision, IS we limited a 
comparison of prevalences to white populations. Our age-specific prevalences were 
similar to the SEE Study' and the Melbourne Visual Impairment Project, 10 but lower 
compared with all other studies. The Beaver Dam and Blue Mountain Eye Studies 
showed substantially higher prevalences.'·s This may be due in part to differences in 
definition because those two studies included a visual acuity of 0.5 (20140) in the 
definition of visual impairment. When comparing only legal blindness, the prevalences 
were still higher, but closer to our data (data not shown). 
A major concern in prevalence studies is non-participation. The Rotterdam Study 
had a reasonable response, but evaluation of differences between participants and 
nonparticipants indicated that nonresponse was selective and may have produced an 
underestimate of the prevalences of blindness and visual impairment. A higher 
proportion of nonparticipants among the oldest subjects is a general problem in studies 
of elderly popUlations, as is the higher nonresponse among subjects with poor physical 
or mental health. Our study consisted of more subjects aged 85 years or older than the 
other studies, and especially for this age-group, the hue prevalence must be even 
higher. We consider it unlikely that non-response influenced the proportions of causes 
of blindness and visual impairment. 
Knowledge of the age-specific causes of blindness elucidates the 'increase in 
prevalence of impaired vision and may facilitate adequate management. In this study, 
most of the disorders responsible for blindness and visual impainnent were age-
related, mostly of unknown cause, and, as yet, unpreventable. We confirm the 
observation that AMD is the leading cause of blindness among white populations,8.18. 
19 but this was hue only for subjects aged 75 years or older. Then it became the main 
contributor to the steep increase in the prevalence of blindness, leading to bilateral 
blindness as a single cause in 12 (3%) of all 408 subjects aged 85 years or older in the 
present study. In common with other studies, age-related cataract was the most 
impOliant cause of bilateral visual impairment,"'o and the second most frequent cause 
of blindness. The visual impairing effect of cataract was highly associated with age, 
causing a larger proportion of visual impairment with increasing age. Successful 
treatment for this disorder is readily available; cataract extraction is one of the most 
frequent surgical procedures in the Netherlands (Netherlands Foundation of 
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Information Systems for Health Care[SIG-Zorginformatie], National Medical 
Registration, Utrecht, the Netherlands)." If adequate facilities and personnel are not 
a logistic constraint to treatment, why does cataract still impair vision to such a great 
extent in the elderly? Before we enlarge on this issue, we emphasize that 62 (15%) of 
408 subjects aged 85 years or older were "saved" from bilaterally blindness or visual 
impairment by cataract-extraction, a much greater proportion than the 32 (8%) that 
were blind or visually impaired by cataract. Most of the subjects in the latter categOlY 
received no eye care. Our study provides limited information on possible barriers, but 
old age, unawareness of treatment possibilities and comorbidity (with other disabling 
disorders) seem to hamper access to appropriate care. Policies to implement referrals 
on a more uniform basis are needed, for even in the vety old or disabled, restoration 
of visual function may improve the quality oflife and reduce the nursing care required. 
Diabetes mellitus was a frequent disorder in our population, but diabetic 
retinopathy rarely led to poor vision. Although findings from studies on subjects with 
diabetes suggest a larger influence of diabetes on visualloss,21." diabetic retinopathy 
was not a major cause of blindness in any of the other population studies of older 
white populations."·20 As described by Stolk et aI," active proliferative retinopathy 
was not observed in the Rotterdam Study. In addition, a low frequency of laser 
photocoagulation scars indicated that the absence of active proliferative retinopathy 
did not directly result from ocular treatment. Selective nonresponse of subjects with 
diabetes with known complications may have occurred, although the frequencies of 
the use of antidiabetic medication between participants and nonparticipants were 
similar. Possible explanations for the small impact of diabetes on vision in this 
relatively old population are selective mortality of persons with diabetes with severe 
systemic complications, the uncommon progression from background retinopathy to 
proliferative retinopathy in the elderly,"·24 and the intensified control of hyperglycemia 
in persons with diabetes."·26 
Our data indicate that age must be specified when determining the frequency of 
causes of visual loss. Appropriate medical care to further reduce the prevalence of 
blindness is not available, but improving accessibility to surgety for the treatment of 
cataract among the old and disabled will help diminish the number of untreated 
cataracts that still leads to visual impairment. 
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Genetic risk of age-related maculopathy 
A population-based familial aggregation study 
Abstract 
Objective: To investigate to what extent ARM is genetically determined. 
D.esign and Setting: Familial aggregation study based on probands derived from the 
population-based Rotterdam Study. 
Participants: First degree relatives of 87 cases with late ARM, i.e., atrophic or 
neovascular macular degeneration, were compared with first degree relatives of 135 
controls without ARM. 
Main Outcome Measures: Presence and stage of ARM as diagnosed on fundus 
transparencies; odds ratio; lifetime risk; risk ratio; population attributable risk. 
Results: Independent of other risk factors, the prevalence of early (OR 4.8; 95% CI 
1.8-12.2) and late (OR 19.8; 95% CI 3.1-126)ARM was significantly higher in 
relatives of cases with late ARM. The lifetime risk estimate of late ARM was 50% 
(95% CI 26%-73%) for relatives of cases versus 12% (95% CI 2%-16%) fort'eiatives 
of controls (P<O.OO I), yielding a risk ratio of 4.2 (95% CI 2.6-6.8). Relatives of cases 
expressed the various features of ARM at a younger age. The population attributable 
risk related to genetic factors was 23%. 
Conclusions: First degree relatives of cases with late ARM developed ARM at an 
increased rate at a relatively young age. Our findings indicate that approximately one 
fourth of all late ARM is genetically determined and suggests that genetic 
susceptibility may play an important role in determining the onset of disease. 
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INTRODUCTION 
ARM is by far the leading cause of blindness in the elderly of developed countries.' 
The prevalence and severity of ARM increase substantially with age. By the age of 80 
years, approximately 10% of patients have developed one of the two late stages of 
ARM, atrophic or neovascular macular degeneration.' Treatment such as laser 
photocoagulation is available for only a minority of patients, and even then 
improvement of visual function is limited.' The growing population of elderly and 
increased life expectancy necessitate research into the causes and risk factors of this 
disease. 
The etiology of ARM is largely unknown, but environmental factors and genetic 
factors have been implicated in the disease. Environmental factors that have been 
associated are cardiovasculat risk factors such as smoking,'·6 atherosclerosis,' and 
estrogens.'·9 A role for genetic factors has been supported by various twin studies;·10 
and by a population-based segregation study." Recent findings from a molecular study 
suggest that the Stargardt ABCR gene may be associated with ARM." 
The presence ofa genetic component may be widely acknowledged, the magnitude 
of its causative role is controversial. Results of two clinic-based studies show familial 
aggregation of ARM and estimate a familial risk of 19.3 and 2.4, respectively."'" 
Possible explanations for this latge difference are the high chance of selection bias 
with hospital-derived probands, the large range of ARM features that were combined, 
and the use of family history and self-reported diagnoses. 
The purpose of this study was to investigate to what extent ARM is genetically 
determined, on the basis of a collection of population-derived pro bands ascertained 
without regard to family histOlY, and selected without regard to any known risk factors. 
We determined the diagnosis of ARM in first-degree relatives by actual examination 
using a standardized protocol, defined the risk of ARM for these relatives, and 
identified those factors associated with increased risk. Furthermore, we aimed to 
quantifY the attributable risk of genetic factors to the overall occurrence of late ARM. 
SUBJECTS AND METHODS 
Collection of families 
All probands were derived from the Rotterdam Study, a population-based prospective 
follow-up study in the Netherlands of subjects aged 55 years and over. The rationale 
and design of the Rotterdam Study have been described elsewhere." 16 In brief, 6775 
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participants were ophthalmologic ally examined; the diagnosis of ARM was based on 
grading of fundus transparencies according to an internationally accepted classification 
system." For the present study, we identified all subjects with atrophic or neovascular 
macular degeneration as case probands (n=IOI). As control pro bands (n=154), we 
randomly selected a sample of study participants who did not have any features of 
ARM, i.e., no soft dl1lsen of intermediate (63-124flm) or large (zI25flm) size and no 
late ARM, i.e., no atrophic or neovascular macular degeneration. Pro bands differed in 
age (mean age of cases vs controls 81.9 vs 76.7 years; P<O.OOI), but not in gender 
(cases vs controls, 63% vs 56% women; age-adjusted P=0.64). Eligible relatives were 
siblings and offspring of cases and controls living in the Netherlands or Belgium who 
could be contacted by letter and telephone. Relatives were invited for an extensive 
screening examination at the research center of the Rotterdam Study, located in 
Onul1oord; those who were homebound were examined at their home. The study was 
approved by the Medical Ethics Committee of Erasmus University, Rotterdam, the 
Netherlands, and written informed consent was obtained from all participants. 
Diagnosis 
The ophthalmological examination included measurements of best-corrected visual 
acuity, ophthalmoscopy, and fundus photography. After mydriasis, 20° stereoscopic 
fundus color transparencies (Topcon TRC-SS2 stereoscopic fundus camera, Topcon 
Optical Company, Tokyo, Japan) and 35° color transparencies (Topcon TRV-50VT 
fundus camera, Topcon Optical Company, Tokyo, Japan) were taken of the macular 
area. Participants who were examined at their home were photographed with a pottable 
camera (35 ° fields, Kowa RC-2 fundus camera, Kowa Corporation LTD, Tokyo, 
Japan). Fundus transparencies were graded for presence of ARM in a masked fashion 
according to the International Classification System," identical to the protocol that was 
used for probands. In accordance with this system, drusen larger than 63 flm, increased 
pigmentation, RPE-degeneration, atrophic macular degeneration (geographic atrophy) 
or neovascular macular degeneration present in the macular grid area (radius, 3000 
flm) were considered outcomes of ARM. These lesions were subsequently stratified 
into four exclusive stages increasing clinical severity: no ARM was defined as the 
absence of any type of soft drusen (>63flm), atrophic or neovascular macular 
degeneration;" preliminary or vety early ARM as the presence of soft distinct dt1lsen 
without pigmentmy irregularities; early ARM as either the presence of soft indistinct 
or reticular dt1lsen or the presence of both soft distinct drusen and pigmentaty 
irregularities; 18,19 and late ARM as the presence of atrophic or neovascular macular 
degeneration, 17 
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Environmental risk factors 
To investigate whether familial aggregation of ARM could be caused by clustering of 
environmental risk factors, we considered smoking, atherosclerosis, and estrogen 
deficiency as potential correlates of ARM. 
Presence of atherosclerosis was non-invasively assessed using ultrasound as 
described earlier.20• 21 Peripheral atierial disease was judged to be present when the 
ankle-brachial systolic blood pressure ratio was less than 0.90. Participants were 
questioned about CUll'ent and fonner smoking by interview, and women were asked 
about age and type of menopause, use of contraceptives and post-menopausal estrogen 
therapy. 
Statistical analyses 
Prevalence of ARM lesions, adjusted for age and gender, was compared between 
siblings of cases and siblings of controls, and between offspring of both groups. The 
prevalence odds ratio was estimated for siblings and offspring of cases using multiple 
logistic regression analysis, with siblings and offspring of controls as reference 
categories, and early and late ARM as outcomes. Odds ratios were adjusted for age and 
gender, and in additional analyses, for smoking, peripheral arterial disease, early 
menopause and exogenous estrogen use. Interaction between genetic factors and 
smoking was studied by performing a stratified analysis and by performing the analysis 
on the full data set, including the product term for smoking and proband status (case 
or control). 
The cumulative risk estimating the lifetime absolute risk of ARM for relatives of 
cases and controls was calculated using Kaplan-Meier product-limit survival analysis 
with early and late ARM as outcomes. Participants above 85 years were pooled to 
maintain unbiased estimates." Cumulative risks were compared between groups using 
the logrank test. 
The attributable proportion of genetic factors to the occurrence of late ARM in the 
exposed and general population was estimated using the formulas presented by 
Miettinen.2J The attributable proportion for genetically exposed (Ape) was calculated 
with the formula 
RR-j Ape=--
RR' 
where RR is the relative risk. The attributable propOliion for the total population (App) 
was calculated with 
App=Ape*Pe, 
where Pe is the proportion genetically exposed in the cases. 
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Table 1. General characteristics . 
Siblings 
of cases of controls 
(n~73) (n~142) 
Age in years (SD) 76 (9) 75 (9) 
Age range (years) 59-96 45-96 
Gender (% women) 55 58 
Smoking (%) Current 18 9 
Fonner 46 49 
Never 36 42 
Peripheral atherosclerosis (%) 12 16 
Menopause < 45 years (%)f 13 13 
Ever used oral contraceptives (%)t 20 15 
Ever used postmenopausal estrogens 16 17 
• Values are given as means (SO) or proportions, adjusted for age and gender. 
t Percentage of women 
I p < 0.001 for the difference with relatives of controls 
RESULTS 
Family description 
Genetic risk a/ARM 
Offspring 
of cases of controls 
(n~1I3) (n~201) 
54 (10)1 49 (9) 
30-74 23-73 
43 46 
32 28 
41 42 
27 30 
5 2 
0 0 
76 86 
16 21 
The overall response of eligible subjects was 83.6%. Of cases, 87 (86.1 %) gave 
permission to contact their families; 34 cases had been diagnosed with atrophic 
macular degeneration and 53 as having neovascular macular degeneration. Of controls, 
135 (87.7%) consented. Of relatives of case probands, 73 (85%) of86 siblings as well 
as 113 (86.2%) of 131 children agreed to participate, of relatives of controls, 142 
(79.8%) of 178 siblings and 20 I (81 %) of 248 children participated. The frequency of 
home visits was equally distributed among the participating relatives of cases and 
controls (16.7% and 17.5%,respectively; P~0.90). 
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Table 2. Prevalence of ARM-characteristics' 
Siblings Offspring 
of cases of controls of cases of controls 
(n~73) (n~142) (n~113) (n~201) 
Drusen 
Largest size, total number 
63-124 ~m 1-9 33 31 32 23 
, 10 8 4 
, 125 ~m 1-9 19' 7 5 2 
,10 7 3 2 0 
Most severe type soft distinct 39 35 34 25 
soft indistinct 17' 6 4 
reticular 0 0 0 
Grid area occupied < 10% 89' 97 96' 100 
by drusen t 10-24% 7' 2 0 
;,:.. 25% 4 2 2 0 
Pigmellfmy irregularities 
Increased pigment 14' 4 4 
RPE-degeneration II' 4 6' 
LaleARM 
Atrophic macular degeneration 10' 0 0 
Neovascular macular degeneration 4 2 0 
• Values are given as proportions in percentages adjusted for age and gender. Features may occur concurrently 
and do not add up to 100%. 
f P < 0.05 for the difference with relatives of controls 
I Circular grid with radius 3000 ,..m centered 011 the fovea 
Table I shows the distribution of age, gender, and risk factors among relatives. 
There were no significant differences in these characteristics between groups, except 
for the age distribution among offspring. Smoking appeared to be more frequent 
among relatives of cases but did not differ significantly from relatives of controls. 
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The prevalences of the various features of ARM are given in Table 2. Although 
siblings had higher frequencies of almost all ARM characteristics than offspring, in 
siblings and offspring these lesions were significantly more frequent among relatives 
of cases than among relatives of controls. Features given in Table 2 may overlap; 
hence, we subsequently calculated the prevalence of ARM by exclusive stages of 
disease. For siblings: the prevalence of no ARM was 35.5% for siblings of cases vs 
57.8% for siblings of controls (P~O.OOI, age and sex adjusted); the prevalence ofvelY 
early signs of ARM was 41.6% vs 37.1% (P~O.52, age and sex adjusted); the 
prevalence of early ARM was 9.5% vs 2.9% (P~O.04, age and sex adjusted); and the 
prevalence of late ARM was 13.4% vs 2.2%, (P~O.OOI; age and sex adjusted) 
respectively. For offspring: the prevalence of no ARM was 57.4% for offspring of 
cases vs 72.4% for offspring of controls (P~O.02, age and sex adjusted); the prevalence 
ofvelY early signs of ARM was 34.9% vs 25.7% (P~O.09, age and sex adjusted); the 
prevalence of early ARM was 6.3% vs 1.9% (P~O.05, age and sex adjusted); and late 
ARM was present only in 1.4% offspring of cases (P~O.20, age and sex adjusted). 
In the nuclear families of cases, 10 siblings and 2 children were identified with late 
ARM. To investigate whether there was an association with subtype of macular 
degeneration, we determined the concordance of subtype in the 12 relative-proband 
pairs with late ARM. The concordance was low as only three pairs had the same type 
of late ARM (neovascular macular degeneration). 
Table 3. Odds ratio of early ARM for first degree relatives of cases' 
Early No ARM OR' (95% CI) OR' (95% CI) 
Siblings of cases 15 22 
Siblings of controls 12 77 
4.5 (1.8-11.3) 4.8 (1.8-12.2) 
Offspring of cases 8 60 
Offspring of controls 3 150 
4.9 (1.2-20.6) 6.6 (1.4, 31.8) 
• Early ARM indicates age-related maculopathy, defined as either the presence of soft indistinct or reticular 
dmsen or the presence of both soft distinct drusen and pigmentary irregularities; OR, odds ratio; and el, 
confidence interval. 
f Adjusted for age and gender 
'Adjusted for age, gender, smoking, and atherosclerosis 
Genetic risk estimates 
Relatives of cases had an increased risk of ARM when compared with relatives of 
controls (Tables 3 and 4). For siblings, the point estimate of the odds ratio increased 
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with greater severity of ARM (odds ratio point estimate of early ARM 4.5; of late 
ARM 14.3). However, confidence intervals were wide. For offspring, the odds ratio 
estimate of early ARM (4.9) was similar to the estimate for siblings. The strength of 
the associations did not diminish after adjustment for smoking and atherosclerosis, or 
after additional adjustment for early menopause and exogenous estrogen use in women 
(latter data not shown), indicating that the associations were not confounded by 
familial clustering of these risk factors. Furthermore, we found no statistical evidence 
for interaction between familial risk and smoking (data not shown). 
Kaplan-Meier product-limit estimates indicated that the lifetime absolute risk of 
developing early ARM by the age of 85 years (Figure I a) was 48% (95% CI=31 %-
65%) for relatives of cases, whereas this risk was 23% (95% CI=IO%-37%) for 
relatives of controls (P=O.OO I), yielding a risk ratio of2.1 (95% C\= lA, 3.1) and a risk 
difference of25%. The lifetime absolute risk of developing late ARM by age 85 years 
(Figure I b) was 50% (95%CI=26%-73%) for relatives of cases vs 12% (95% C\=2%-
16%) for relatives of controls (P<O.OO 1), yielding a risk ratio of 4.2 (95% CI=2.6-6.8) 
and a risk difference of38%. Although the pattern was most pronounced for late ARM, 
both cumulative risk curves showed similar patterns, with an earlier rise in risk for 
relatives of cases. When relatives were stratified by proband gender, no significant 
evidence for difference in risk of early or late ARM was obtained. When relatives were 
stratified by proband subtype of ARM, i.e., atrophic or neovascular macular 
degeneration, there was no significant difference in cumulative risk of early ARM. 
This showed that genetic risk was not confined to gender or subtype of late ARM. 
Table 4. Odds ratio of late ARM for first degree relatives of cases' 
Late ARM No ARM ORt (95% el) OR' (95% CI) 
Siblings of cases IO 22 
Siblings of controls 3 77 
14.3 (3.0·67.8) 19.8 (3.1·126) 
Offspring of cases 2 60 
Offspring of controls 0 150 
'Lale ARM indicates age-related maculopathy, defined as the presence of atrophic or neovascular AMD; 
OR, odds ratio; el, confidence interval. 
f Adjusted for age and gender 
fAdjusted for age, gender, smoking, and atherosclerosis 
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Attributable risk 
We restricted the calculation of the attributable risk related to genetic factors to late 
ARM because this is the clinically most relevant stage and the diagnosis on which 
cases had been selected. The attributable propotiion, or excess case load, was 
calculated for the genetically exposed patiicipants and for the total population using 
the ratio ofthe cumulative risks oflate ARM in relatives as the best approximation of 
the hue relative risk for genetic factors (RR=4.2) in the Ape and App formulas. The 
attributable propotiion among the genetically exposed (Ape) was 76%, i.e., in 76% of 
the participants with a familial occurrence the disease may be attributed to a genetic 
component. We estimated the proportion of exposed cases (Pe) as the ratio of case 
probands with affected relatives divided by all case probands with relatives who were 
at least 68 years old, which was the minimum age oflate ARM onset in our study. This 
proportion was 120[39, and subsequently we calculated that the proportion of late 
ARM in the total popUlation that may be attributed to a genetic component (App) was 
23%. 
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DISCUSSION 
We demonstrated that ARM aggregates in families of a general white population, 
which we cannot attribute to clustering of known risk factors. Independent of smoking, 
atherosclerosis and early menopause, first degree relatives of cases with late ARM had 
a substantial excess risk of developing ARM. Their life time absolute risk to be 
likewise affected by late ARM was 50%. Results of our study suggests that almost one 
f0U11h of all late ARM in the general population may be caused by a genetic 
component. 
The design of our study has several benefits. First, we took advantage of the 
database from the Rotterdam Study, which included detailed information on ARM in 
a population-based setting. This enabled us to ascertain probands without knowledge 
of family history and without regard to any known risk factors. Previous studies have 
used hospital registries for sampling probands, where differential referral of patients 
according to family histOlY Or other correlates of disease may have distorted results. 
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Second, in contrast to others, we did not rely on family histOlY but actually examined 
all first-degree relatives. Third, because ARM is clinically heterogeneous with a large 
range of variance in its manifestations and an age-dependent penetrance, enforcement 
of standard clinical criteria is impOliant. We based the diagnosis of ARM on a masked 
grading offundus transparencies using internationally accepted criteria. For probands 
we used rigorous criteria and selected cases and controls who were at either end of the 
clinical spectnull to improve classification of truly affected and unaffected pmiicipants. 
By contrast, we registered all characteristics of ARM in relatives and stratified them 
according to stage of disease to study aggregation of the entire spectnull of ARM in 
the families. 
There are also several limitations to our study. The size of the study was relatively 
small, which resulted in imprecise risk estimates, and low statistical power to detect 
interaction with environmental factors. Only larger studies can overcome this problem. 
Another issue is the age-distribution of the study participants. Although siblings of 
both groups were similar in age, offspring of cases were significantly older than 
offspring of controls. This may have distOlied the prevalence odds ratios for offspring 
estimated with logistic regression analysis. Distortion of other risk estimates is less 
likely, because they were based on the Kaplan-Meier analysis which carefully accounts 
for age at examination. The last point is the limited study of potential confounding 
variables. The environmental factors that we considered were those risk factors 
identified in the Rotterdam Study."" 7.8 Other environmental factors such as diet'" 25 
and cholesterol level" have been suggested, but the risk associations are inconclusive 
and could not be replicated in the Rotterdam Study (Vingerling and Klaver, 
unpublished data). Simple clustering of unknown risk factors may partly account for 
our findings, but it has been shown that genetic factors are the most likely explanation 
for strong familial aggregation. 27 
The notion has long existed that genetic susceptibility is one of the strongest risk 
factors for ARM apart from advanced age. However, it has remained unclear to what 
extent ARM is genetically determined. We based the relative risk for a genetic 
component on the proportions affected in relatives of affected and unaffected subjects, 
and estimated the odds ratio and the ratio of cumulative lifetime risks. The latter was 
estimated with Kaplan Meier product-limit analysis, which censored participants who 
had not developed the disease at the time of examination and thereby accomplished an 
adjustment for age-dependent expression. Given this benefit, the 4.2 ratio of 
cumulative lifetime risks is the better estimate of the true lifetime relative risk oflate 
ARM for first degree relatives. We based the attributable risk on this ratio and on the 
proportion exposed cases, considering those having an affected relative to be exposed. 
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We limited our analysis to cases with relatives aged 68 years or older, but our 
proportion of 23% may be an underestimation of the tme attributable risk if exposed 
cases have relatives who have not developed the disease. 
Although both cumulative risk curves of ARM demonstrated an exponential rise in 
risk, the curve for relatives of cases shifted to the left, suggesting that a strong effect 
of familial predisposition is an earlier onset of disease. This contention is suppotted by 
the observation that the frequencies of ARM features were remarkably similar between 
offspring of cases and siblings of controls, whereas they differed approximately 20 
years in age (Table 2). Unfottunately, our study had no information on age of disease 
onset, and we, therefore, could not make a distinction in familial risk for probands with 
early vs late onset of ARM. A higher risk for probands with an early onset would have 
added to the evidence of an association between age at onset and familial risk. 
Nevertheless, it is an interesting observation that needs further exploration, for 
knowledge of this relation will direct genetic research to focus on subjects with a high 
familial risk of disease. 
Whether differences in phenotypic manifestations of ARM reflect differences in 
genetic background has been subject for debate. Various reports describe familial 
occurrence of dmsen only,'"29 whereas Klein et apo report a striking similarity of late 
ARM features in monozygotic twins. On the other hand, a recent publication30 
repotting eight families with a high prevalence of ARM describes a large variance of 
ARM features among relatives. We compared families of subjects with late stages of 
ARM with families of participants without any manifestations of disease, All early and 
late manifestations of ARM occurred more frequently among relatives of cases. 
Concordance of ARM features between family members was low apart from stage of 
disease, and there was no difference in familial risk between probands with atrophic 
vs neovascular macular degeneration, Hence, genetic susceptibility to late ARM 
increased expression of all manifestations of ARM, with the highest risk for either type 
oflate ARM, 
In conclusion, we showed that all manifestations of ARM occur at a higher 
frequency and at an earlier age in relatives of cases with late ARM. The high relative 
and attributable risks demonstrate that genetic factors playa major role in the cause 
and overall occurrence of ARM. Further studies are needed to reveal whether this 
genetic contribution is mainly caused by a major gene, the result of several genes, or 
involves interaction with other risk factors, This will improve understanding of the 
molecular basis of this disease and may eventually lead to strategies for prevention and 
treatment. 
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Heterogeneity of the genetic risk in age-related 
maculopathy 
Abstract 
Earlier studies demonstrated an increased risk of age-related maculopathy (ARM) 
for first degree relatives of affected subjects. We aimed to assess whether the 
genetic risk of ARM shows heterogeneity among families. Case (n=64) and control 
(n=IOO) probands were selected from the population-based Rotterdam Study, and 
tirst degree relatives were examined for diagnosis of ARM by fundus photography. 
The family score method was used to estimate a risk for each family taking into 
account the risk of disease expected on the basis of age. Families of cases were at a 
higher risk of ARM than families of controls. Familial heterogeneity of risk was 
suggested within the case families, with 17% at low familial risk of ARM, 13% at 
intermediate risk, and 3% at high familial risk of ARM. Subjects with an 
intermediate or high familial risk were 30 times (OR 29.9, 95% CI 3.4, 262) more 
likely to develop ARM than subjects with no excess risk. Our results show that the 
risk of ARM varies among families, and suggest that only a small fraction of all 
ARM is due to a strong genetic component. 
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INTRODUCTION 
Age-related maculopathy (ARM) is becoming a frequent eye disease as the 
population ages, and it is currently the leading cause of blindness in developed 
countries.' It has been well recognized that genetic factors are implicated in the 
etiology of the disease,2,3 but estimates of the strength of this component vary 
significantly. The relative risks reported for first degree relatives of cases ranges 
from 2.4 to 19.3.'·5 One study suggested that ~ 56% of the total ARM variability was 
compatible with a single major gene.' In a previous familial aggregation study 
based on probands from the Rotterdam Study, we estimated that the life time 
relative risk of end stage ARM was 4.2 (95% CI 2.6, 6.8) for first degree relatives 
of cases, and calculated that genetic factors attributed -23% to all end stage ARM 
in the population.' 
Although the ABCR and APOE genes have been associated with ARM, the 
knowledge of the disease-causing genes is Iimited.'·11 Most former study designs 
regarded ARM families as a genetically homogeneous population. In a complex 
disease such as ARM, that is rather unlikely. Presumably, there are families with a 
strong genetic susceptibility as well as families with only a mild or no genetic risk, 
and the relative frequencies of these families will determine the overall magnitude. 
In addition, knowledge of the familial risks is patiicularly relevant for clinical 
counseling. 
In this report, we further explored the data of our previous familial aggregation 
study with the aim to detect variation in risk among ARM families. For each family, 
we calculated a risk score based on observed and expected number of affected 
relatives using demographic and epidemiologic data." This methodology allowed 
us to discriminate between high and low risk families, to investigate their 
frequencies, and to assess their risk differences. 
SUBJECTS AND METHODS 
Collection of families 
Design of the familial aggregation study and methods of data collection have been 
described previously.,,13 In brief, all probands were identified from the baseline 
phase of the Rotterdam Study; case probands (n= I 0 I) were all subjects with 
atrophic or neovascular macular degeneration, and control probands (n=154) were a 
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. randomly selected sample of study subjects who did not have any soft drusen 
(~6311m), nor any atrophic or neovascular macular degeneration. Probands differed 
in age (cases mean age 81.9 years vs controls 76.7 years, P<O.OOI), but not in 
gender (cases 63% women vs controls 56% women, age-adjusted P = 0.64). 
Genealogical data of the last five generations were obtained from probands; no 
probands were genealogically linked. First degree relatives were subsequently 
invited for a screening examination at a research center or at home. 
Diagnosis of ARM 
The ophthalmologic examination included fundus photography of a 20° and 35° 
macular field with a stereoscopic (Topcon TRC-SS2 stereoscopic fundus camera, 
Topcon Optical Company, Tokyo, Japan) and monoscopic camera (Topcon TRV-
50VT fundus camera, Topcon Optical Company, Tokyo, Japan). Subjects who were 
examined at home were photographed with a portable camera (35° field, Kowa RC-
2 fundus camera, Kowa Corporation LTD, Tokyo, Japan). Fundus transparencies 
were graded for presence of ARM features in a masked fashion according to the 
International Classification System, identical to the protocol that was used for 
probands." ARM was stratified in two stages of disease. Early ARM was defined as 
the presence of either soft distinct dntsen with pigmentmy changes or the presence 
of soft indistinct or reticular drusen. Late ARM was defined as the presence of 
atrophic (geographic atrophy) or neovascular AMD. 
Table 1. Age-specific prevalence (%) of ARM in the baseline phase of the 
Rotterdam Study, 1989-1993 
Age (years) Early ARM Late ARM Total ARM 
55 - 59 2.2 0.2 2.4 
60 - 64 3.2 0.1 3.3 
65 - 69 5.t 0.5 5.6 
70 - 74 10.6 0.8 ItA 
75 - 79 12.6 1.7 14.3 
80 - 84 14.8 6.5 21.3 
85 - 89 18.5 9.2 27.7 
90+ 21.2 17.7 38.9 
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Statistical analyses 
Age-specific prevalences of ARM were determined from the baseline phase of the 
Rotterdam Study,12 and they served as the expected outcome of ARM for each 
relative (Table I). For each family, the expected number (EI ) of affected relatives 
for the ith family was compared to the observed number (0,) to give a family score 
(FS) for this family as 
This is a modified versIOn of the method originally described by Houwing-
Duistermaat et a1. 15.16 
Family scores were subsequently stratified in four risk groups: no increased risk 
(FS < 0.5); low risk (0.5 s FS < I); intermediate risk (0.5 s FS < I); and high risk 
(FS 2 2).15.17 The relative frequencies of these strata were calculated. The risk of 
ARM was estimated for each stratum using logistic regression analysis, adjusting 
for the possible confounding effect of age, sex, smoking, and atherosclerosis. 
Table 2. General characteristics of the study population 
Total no. of relatives 
No. of siblings 
Mean age of siblings, yrs, ± SD 
% women among siblings 
No. of offspring 
mean age of offspring, yrs, ± SD 
% women among offspring 
Case families 
(n = 64) 
186 
73 
76.0 ± 8.7 
55 
113 
53.7 ± 10.4' 
43 
• p < .00 I for the difference with relatives of controls 
88 
Control families 
(n=100) 
343 
142 
75.4 ± 9.4 
59 
201 
48.8 ± 8.9 
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RESULTS 
Of case probands, 87 (86%) subjects consented to participation in the familial 
aggregation study; of control probands, 135 (88%) responded. Of the relatives of 
cases, 73 (85%) siblings and 113(86%) children responded. Of relatives of controls, 
these responses were 142 (80%) and 201(81%), respectively. This resulted in 64 
case families and 100 control families available for the family score analyses. Table 
2 shows the distribution of age, gender, and composition of the families; table 3 
shows the number of affected and unaffected relatives among case and control 
families. 
Table 3. Frequency of ARM among first degree relatives pel' family' 
No. ofrclatives 
affected 
Case families! 
(n = 64) 
o 41 (64) 
14 (22) 
2 7 (11) 
3+ 2 (3) 
• Frequencies in numbers (percentages) 
Control families 
(n = 100) 
84 (84) 
15 (15) 
0(0) 
I (I) 
f The difference in distribution of number of affected relatives between cases and controls was 
statistically significant, P=O.002 
The individual family scores ranged from -0.9 to 3.3 in the entire study group. 
Table 4 shows the distribution of family scores among cases and controls. The 
family scores in the case families varied from -0.7 to 2.7. Eight families had a 
family score between I and 2, and 2 families had a score above 2. No significant 
differences were found in distribution of low, medium, and high family scores 
between probands with atrophic and neovascular AMD (data not shown). The 
family scores in the control families ranged from -0.9 and 0.8 with an outlier of one 
family with a family score of 3.3. This family consisted of 12 relatives of whom 
four were affected. Two affecteds were relatively young and largely determined this 
high family score. The control proband in question was still unaffected at the time 
of this analysis. 
89 
Chapter 6 
Table 4. Distribution of Family Scores in risk categories among case and 
control families' 
Family score Case families t Control families 
(n~64) (n~IOO) 
FS<0.5 no risk 43 (67) 90 (90) 
0.5 < FS< I low risk II (17) 9 (9) 
I s FS< 2 intermediate risk 8 (13) 0(0) 
FS,2 high risk 2 (3) I (I) 
• Frequencies in numbers (percentages) 
t The difference in distribution of FS between cases and controls was statistically significant, 
P~0.0004 
In Figure lA and 1B, the relative frequencies of family scores are plotted. 
Among cases, there was a peak around zero with a skewed tail composed of 
families with higher than expected rates of ARM. Among controls, the distribution 
of the family scores was, apart from the outlier, centered around O. 
Table 5 shows the odds ratio of ARM for each risk stratum adjusted for age and 
gender, and smoking and atherosclerosis. Intermediate and high risk families were 
pooled since no control families contributed to the intermediate risk group. The risk 
of ARM increased with higher family scores; these risks fmiher increased after 
additional adjustment for smoking and atherosclerosis. 
Table 5. Odds ratio's of ARM for low, intermediate, and high family scores 
Family score ARM no ARM OR (95%CI)' OR (9S%CI)t 
FS<0.5 no risk 43 90 reference reference 
0.5 < FS < I low risk II 9 2.8 (1.0, 7.8) 6.6 (1.8, 23.7) 
FS, I intennediate and 10 29.9 (3.4, 262) 47.1 (4.6,484) high risk 
"Adjusted for age and gender of proband 
'Adjusted for age, gender, smoking, and atherosclerosis 
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A Case Families (n= 64) 
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Figure 1. Freqllellcy (%) of family scores ill case (A) alld cOII(ro[ (B) families 
DISCUSSION 
In this analysis, we demonstrated familial heterogeneity of the ARM risk using a 
family score method. I'·" The majority of ARM families did not appear to have 
higher frequencies of disease than expected on the basis of their age distribution. 
However, 17% of families had a low increased risk, 13% an intermediate risk, and 
3% a high of disease, much higher than expected by the age distribution of the 
family members. Subjects with an intemlediate or high familial risk were at least 30 
times more likely to be affected than subjects with no excess familial risk. This 
increased risk could not be explained by the known risk factors smoking and 
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atherosclerosis; on the conh'my, the risk accrued when the effect of these factors 
was taken into account. 
There are several advantages of the design and method of analysis in this study, 
In contrast to former familial risk analyses of ARM which pooled relatives from 
different families, we used a family score method which regarded individual 
families as the unit of analysis. This strategy was developed earlier for modeling 
family history in logistic regression models."·16 Per family, the observed number of 
affected relatives was compared with the expected number, resulting in a risk 
estimate for each family. An important benefit is that this allowed for 
discrimination of risk in families from the same proband group. Other sh'engths of 
the study include the calculation of the expected ARM risk from the age-specific 
prevalences in the Rotterdam Study, the same source population as where the case 
and control probands originated from. Moreover, relatives were actually examined 
and photographed, and the diagnostic criteria for observed and expected number of 
affected relatives, as well as for cases and controls, were identical. 
Among the limitations of our approach is, that consideration of the family as the 
unit of analysis created loss of statistical power. Due to the relatively small number 
of families, and the small number of relatives per family, statistical significance 
between familial risk strata could not be achieved. For the total number of families 
that were studied, we were limited by the frequency of ARM in the Rotterdam 
Study. Increasing the number of families and expanding the study population with 
second degree relatives would improve precision of the risk estimates. Another 
issue is that our study population consisted of prevalent rather than incident cases, 
leading to misclassification of family scores due to an unknown age of onset. On 
the other hand, this will be the situation encountered in clinical practice. By using 
age-adjusted prevalences for the expected number of relatives, the excess familial 
risk was adjusted for age at examination. Finally, control probands were on average 
younger than case probands, and may have harbored 'subclinical' familial cases of 
ARM. The effect of this potential misclassification appeared to be small, for 
observed family scores were close to the expected score among the control 
families. The exception was one family with four relatives affected, of whom the 
proband was still unaffected at the age of 87 years. 
Given these considerations, what can be learned from this study? Our data 
emphasize that ARM is a genetically complex disorder, which can not readily be 
explained by one single major gene.' On the contrmy, the large range in familial 
risk indicates that the genetic contribution to disease differs considerably among 
families. In the high risk families, the disease is probably caused by a strong 
genetic factor with a Mendelian inheritance. However, this proportion of families 
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factor with a Mendelian inheritance. However, this proportion of families appears to 
be small. In the majority of ARM families, multiple etiologies are involved: some 
genetic, some environmental, and most likely a combination of these. 
In summmy, the results of this analysis complement our earlier findings.' We 
confinned that families of cases are at an increased risk of ARM, but now 
demonstrated that the variation in familial risk is large. The classification of ARM 
families into high, intermediate, and low risk families may allow molecular genetic 
studies to focus on the appropriate risk groups in the search for disease-causing 
genes. 
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Genetic association of apolipoprotein E with age-
related macular degeneration 
Abstract 
Age-related macular degeneration (AMD) is the most common geriatric eye disorder 
leading to blindness and is characterized by degeneration of the neuro-epithelium in 
the macular area of the eye. Apolipoprotein E (apoE), the major apolipoprotein of the 
central nervous system and an important regulator of cholesterol and lipid transport, 
appears to be associated with neurodegeneration. The apoE gene (APOE) 
polymorphism is a strong risk factor for various neurodegenerative diseases, and the 
apoE protein has been demonstrated in disease-associated lesions of these disorders. 
Hypothesizing that variants of APOE act as a potential risk factor for AMD, we 
performed a genetic association study among 88 AMD cases and 901 controls derived 
from the population-based Rotterdam Study in the Netherlands. The APOE 
polymorphism showed a significant association with the risk for AMD; the APOE E4 
allele was associated with a decreased risk (odds ratio 0.43 [95% CI 0.21-0.88]), and 
the E2 allele with a slightly increased risk of AMD (odds ratio 1.5, [95% CI 0.8-2.82]). 
To investigate whether apoE is directly involved in the pathogenesis of AMD, we 
studied apoE immunoreactivity in 15 AMD and 10 control maculae and found that 
apoE staining was consistently present in the disease-associated deposits of AMD-
maculae, that is, drusen and basal laminar deposit. Our results suggest that APOE is 
a susceptibility gene for AMD. 
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INTRODUCTION 
AMD is the most common cause of blindness in the elderly in developed countries, 1-4 
severely affecting over 10% of octo- and nonagenarians.5 Histopathologically, the 
hallmark of early AMD is accumulation of extracellular drusen and basal laminar 
deposit,6-8 the end stage is characterized by a complete degeneration of the 
neurosensory retina and of the underlying retinal pigment epithelium in the macular 
area.9 The etiology of AMD is largely unknown, but the current understanding is that 
AMD is a genetically complex eye disorder lO- 12 possibly caused by a variety of 
molecular defects. Less frequent macular disorders have been linked to a significant 
number of genomic loci, 13-18 whereas mutations in the TIMP3 19 and peripherinlRDS20-25 
-genes have been identified in specific earlier-onset retinal dystrophies. Despite close 
clinical similarities with these disorders, neither the TIMP3 gene nor the 
peripherin/RDS gene have been associated with AMD. A recent publication reports 
that the Stargardt disease gene shows a consistent variation of the ABCR gene in 4.2% 
of AMD patients, significantly different from the 0.45% in population controls.26 This 
variation may account for approximately 4% of the total occurrence of AMD, and, 
presumably, more genes are involved. 
Apolipoprotein E (apoE) is unique among apolipoproteins in its special relevance 
to nervous tissue. It mobilizes and redistributes lipids, in maintenance and repair of 
neuronal cell membranes 1988;27-29 thereby playing a pivotal role in the reinnervation 
process following peripheral injury30 and central nervous system injury.31 The gene for 
apoE (APOE), located on chromosome 19q13.2,32 is polymorphic, with the occurrence 
of three common alleles: E2, E3, E4. The E3 allele is considered to be the ancestral 
allele; and E2 and E4 are considered as variants by single point mutations. 28 APOE's 
polymorphism is of particular interest within the framework ofneurodegeneration, for 
it is strongly associated with the risk of Alzheimer disease 34,35 and may be associated 
with various other neurodegenerative disorders. 36,37 Moreover, apoE is expressed in 
lesions that characterize Alzheimer disease, Down syndrome, and prion diseases.38,39 
Expanding these data to a neurodegenerative eye disorder, we investigated the 
possible role of APOE in AMD in a genetic association study. We have used a case-
control design implemented within a population-based study, to assess whether the 
APOE alleles are associated with the risk of AMD. In a subsequent 
immunohistochemical procedure, we studied apoE expression in human maculae with 
and without AMD. 
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SUBJECTS AND METHODS 
We studied APOE genotype and allele frequencies in AMD-cases and controls derived 
from the Rotterdam Study, a population-based study, in the Netherlands, of subjects 
aged 55 years and over. The rationale and design of the Rotterdam Study are described 
elsewhere.5,4o A total of 6775 participants in that study had undergone an extensive 
ophthalmological examination, including fundus photography. Diagnosis of AMD was 
based on grading of fundus transparencies according to an internationally accepted 
classification system.41 Cases were all subjects with end stages of AMD of whom data 
on APOE genotype were available (n=88). The end stages comprised atrophic macular 
degeneration, that is, geographic areas of atrophy of the retinal pigment epithelium 
and choriocapillaris, and neovascular macular degeneration, that is, serous or 
haemorrhagic detachment of the pigment epithelium or choroidal neovascularization. 
Controls were a randomly selected sample of study subjects without atrophic or 
neovascular AMD (n=901). There were no significant differences in baseline 
characteristics between cases and controls apart from the known risk factors age and 
atherosclerosis. (Mean age [SD]: 81 [8] vs 69 [9] years, P< 0.00 I; frequency oflower-
extremity arterial disease [an indicator of atherosclerosis] 37% vs 16%, P<O.OOI [age-
adjusted prevalence data]). 
Genomic DNA was extracted from peripheral blood leucocytes, and the subsequent 
analysis of APOE genotypes was performed as described elsewhere.42,43 Genotype and 
allele distributions between cases and controls were calculated by use X2 statistics. 
With multiple logistic-regression analysis, we estimated the odds ratio (OR), as a 
measure of relative risk, for the various genotypes, using the ancestral E3E3 genotype 
as a reference. ORs were adjusted for age and gender and, in a separate analysis, for 
presence of lower extremity arterial disease, to investigate the possible confounding 
effect of atherosclerosis. 
For the immunohistochemical study, maculae were obtained from 25 human eye-
bank eyes from 25 subjects. The times from death to processing of the maculae ranged 
from 1-10 hours, with a mean of 7 hours. Tissues were fixed in 4% formaldehyde, 
embedded in paraffin, and sectioned into 5 /lm thickness. Sections were stained with 
hematoxylin-eosin, the periodic-acid-Schiff reaction, and Mallory staining and 
subsequently were classified histologically according to quantification of drusen and 
basal laminar deposit, as described elsewhere.6,8 Accordingly, maculae with no or only 
solitary patches of basal laminar deposit and with no more than three drusen were 
classified as controls (n= 10); maculae with a continuous layer of basal laminar deposit 
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and/or with many or confluent drusen were classified as cases (n=15). Cases were, 
although non-significantly, older than controls (mean age [SD]: 82 [10] vs 72 [14] 
years, P = 0.08). After deparaffinization and rehydration, sections were incubated with 
5.5 mU/ml pronase E (Sigma), to reveal antigenic epitopes of APOE, and were placed 
in a Sequenza Immunostaining Workstation (Life Sciences International). Sections 
were successively incubated with a mouse-monoclonal antibody directed against apoE 
(clone 3D12, dilution of 1 :25, Monosan), biotinylated-secondary antibodies (Multilink, 
dilution of 1:75, Biogenex), and alkaline-phosphatase-conjugated streptavidin (dilution 
of 1 :50, Biogenex). Between these incubations, sections were washed thoroughly with 
phosphate-buffered saline. After final rinsing with 0.2 M Tris-HCI pH 8.0, the 
presence of apoE was visualized with 0.3% New FuchsiniTris-HCI (Sigma). 
Table 1. Distribution of APOE genotypes and allele frequency 
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APOE characteristics 
Genotype 
E2E2 
E2E3 
E2E4 
E3E3 
E3E4 
E4E4 
Allele Fequency 
E2 
E3 
E4 
" P=O.02 versus controls; 
AMD cases 
(n=88) 
0.000 
0.227 
0.023 
0.636 
0.114' 
0.000 
0.125 
0.806 
0.068b 
b P=O.004 versus controls; Hardy-Weinberg equilibrium: 
cases X2 2.27, P=O.26; controls X2 4.24, P=O.11 
controls 
(n=901) 
0.010 
0.144 
0.017 
0.555 
0.252 
0.022 
0.090 
0.753 
0.156 
(J) 
<l) 
'0 
c 
<l) 
::::l 
0-
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<l) 
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Figure 1. APOE allele frequellcies ill age-categories 55-75 years, 75-85 years alld ;c85 years. 
The lIumber of cases alld the lIumber of COli troIs, respectively, ill the successive categories 
are 17 alld 687,40 alld 188, alld 26 alld 31. The proportiollal areas (sub-bars) illdicate the 
relative allele frequellcies of the E2, E3, alld E4 alleles ill AMD-cases alld ill COli trois 
RESULTS 
APOE genotype and allele distributions differed significantly between cases and 
controls (Table 1). Compared with controls, the frequency of the APOE E4 allele was 
significantly lower among cases (0.07 in cases vs 0.16 in controls, P=0.002), whereas 
the frequency of the E2 allele was, although not-significantly, higher (0.13 vs 0.09, 
P=0.17 ). Because the E4 allele may adversely affect longevity given its association 
with Alzheimer disease and coronary heart disease,44 we investigated the prevalence 
of the APOE alleles as a function of age (Figure 1). There were no significant 
differences in allele frequencies in the three age groups, indicating that our findings 
cannot be explained by the age-distribution difference between cases and controls. 
Table 2 shows the relative risks of AMD for the different APOE alleles. When 
adjusting for age and sex, subjects with the E4 allele were more than two times less 
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likely to develop AMD than were subjects with the E3E3 genotype. Subjects with the 
E2 allele were at a slightly, but non-significantly, increased risk of AMD. Additional 
adjustment, for lower extremity arterial disease, did not significantly alter the risk 
estimates (data not shown), suggesting that APOE and atherosclerosis are independent 
risk factors for AMD. 
Table 2. Risk of AMD" for the APOEb genotypes 
APOE AMD Controls Crude ORo Adjusted ORd 
genotype' (n=88) (n=901) (95% CI) (95% CI) 
E*2 22 154 1.28 (0.75-2.21) 1.50 (0.80-2.82) 
E3E3 56 500 reference reference 
E*4 12 262 0.41 (0.22-0.78) 0.43 (0.21-0.88) 
'Age-related macular degeneration bApolipoprotein E 
<Odds ratio d Adjusted for age and gender 
'APOE genotypes with the E2 allele are grouped, and genotypes with the E4 allele are grouped. Subjects 
with the E2E4 genotype (2 of88 cases, 15 of901 controls) are present in both the E*2 and the E*4 group. 
ApoE immunoreactivity was present in the extracellular deposits that characterized 
the AMD maculae, that is, basal laminar deposit and soft drusen. Basal laminar deposit 
stained positive for apoE in 13 of 15 maculae with this type of deposit (Figure 2A), and 
drusen stained positive in 9 of 11 maculae with drusen (Figure 2B). One eye with 
atrophic AMD showed both a thick layer of basal laminar deposit and drusen staining 
positive for apoE (Figure 2C). In both case and control maculae, staining was seen in 
the outer collagenous zone of Bruch's membrane, in blood vessels, and in Muller cells. 
Particularly of interest is the finding that solitary, hard hyaline drusen, a type of 
deposit that is clinically not associated with AMD, did not show any apoE 
immunoreactivity. 
DISCUSSION 
Our results show that the APOE gene polymorphism is significantly associated with 
the risk of AMD and that apoE is expressed in lesions that characterize AMD. A 
decreased risk of AMD was associated with the E4 allele, whereas an increased risk 
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Figure 2. IlIIlIIlIlIoltislocllelllisll'Y of apoE ill It 11111 all lIIaclllae witlt AMD (Ne,v Fucltsille, 
x400). SIIO'VII is positive staillitlg (III I'ed) of (a) a tltill layel' of basal {alii ill al' deposit located 
betweell tlte I'etillaipiglllellt epitltelilllll (I'pe) am{ BI'I/clt 's lIIelltbl'rtlle (al'l'ow); (b) soft d/'llsell 
(al'l'ows); am{ (c) Iltick {ayel' ofdifftlse dl'lISell ill sllbjeclwltlt AMD. (Note disappeal'allce of 
tlte pllOtol'eceptol'S alld 1II0St of tile 11Je.) ONL = olltel' 11I1e/eal' {ayeI'; PH = pltolol'eceptol's 
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was associated with the E2 allele. The consistent immunoreactivity in soft drusen and 
basal laminar deposit in the AMD maculae suggests importance of apoE in the 
pathogenesis of AMD. 
We carefully avoided selection bias, a frequently encountered problem in 
association studies. Since cases and controls were both derived from the same 
homogeneous source population, and the distribution of the APOE genotypes in cases 
and controls was in Hardy-Weinberg equilibrium, selection on the basis of genotype 
is unlikely. Moreover, the allele frequencies among the controls were in close 
agreement with the average allele frequencies estimated for the Dutch45 and other 
Caucasian populations.46 Because our extensive ophthalmologic examination 
demanded attentiveness from the study subjects, it may have selected against other 
neurodegenerative diseases - such as Alzheimer disease - which are known to be 
associated with increased E4 frequency. Nevertheless, this cannot account for 
differences in allele frequencies between cases and controls, because both groups 
underwent identical procedures. Finally, we showed that allele frequencies were 
similar across all age groups (figure 1), indicating that the association cannot be 
explained on the basis of age. 
Given the limited amount of data available, we can only speculate on the possible 
role of apoE in the neuronal dynamics of the macular area. In the central nervous 
system in general, a major physiological role for apoE is to mediate the interaction of 
apoE-containing lipoproteins and lipoprotein receptors, including the low density 
lipoprotein (LDL) receptor47 and the LDL receptor-related protein receptor (LRP).48 
After neuronal cell loss, large amounts of lipids are released from degenerating cell 
membranes and myelin, and, in response, astrocytes synthesize apoE, to bind the free 
cholesterol and lipids and distribute them for reuse in cell membrane biosynthesis.31.49 
ApoE may have a significant role in retinal membrane renewal. The high turnover of 
photoreceptor membranes,5o especially in the macular area, makes cell membrane 
remodeling of critical importance for maintaining the normal physiology of the retina. 
Failure of this process may then result in macular degeneration. 
In the central nervous system, apoE is primarily synthesized by the major glial cell, 
the astrocyte. In our series, cell bodies of the Muller cell, the retinal analogue of the 
astrocyte, showed significant apoE expression, which may indicate a site of apoE 
production. This assumption is supported by findings from previous reports, which 
show that these cells are capable of apoE synthesis51 and which show increased 
expression in eyes with retinal damage. 52 The distribution of the LDL or LRP receptor 
in the neuroepithelium of the eye is unknown, and it is therefore unclear which cells 
are able to take up and process apoE-complexed molecules in this compartment. The 
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retinal pigment epithelium cell, which has digestion of photoreceptor outer segments 
as its primary function, may be an appropriate candidate. 
Interestingly, we found a reduced risk of AMD for subjects carrying the E4 allele, 
whereas for most other neurodegenerative disorders the risk is increased for these 
subjects. Isoform-specific alterations in apoE-lipoprotein metabolism consist of 
differences in net charge46 and total serumS3 and brain level of apoE.S4 Recently, it has 
been shown that the isoforms also differ in cell-specific binding properties.33 The apoE 
mediated binding, internalization and degradation of lipids in the central nervous 
system appear to be different for each apoE isoform, depending on the type of target 
cell. A possible interpretation of our findings is that apoE isoforms in the macular area 
may either differ in binding affinity or elicit a response different than that at other sites 
in the nervous system. Since it is not immediately clear how the APOE alleles may be 
a source of genetic risk for AMD, it will be intriguing to investigate whether 
accumulation of deposits in AMD occurs in an isoform-dependent manner. 
An alternative explanation to our findings is that the E4 allele is associated with a 
distinct mutation in a gene in linkage disequilibrium with APOE. This may be the gene 
that actually determines susceptibility to AMD. According to the August 1997 OMIM 
(Online version of Mendelian Inheritance in Man), 20-30 genes are located in the 
immediate vicinity of APOE, and they may be considered in this context; among these 
genes, we could not find an obvious candidate gene for retinal disease. 
To conclude, we have shown a significant association between the APOE gene and 
AMD in a general population of elderly people, and we have immunohistochemically 
localized the apoE protein in defining lesions of AMD. Although in need for 
confirmation, our data further emphasize the role of APOE in neurodegeneration and 
may indicate that we have identified a susceptibility gene for AMD. 
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Chapter 
Smoking is also associated with age-related 
macular degeneration in persons aged 85 years 
and older 
The article by Vingerling et at, I published in the October 1996 issue of the 
ARCHIVES, describes the association between smoking and age-related macular 
degeneration (AMD). Smoking increased the risk of macular degeneration only in 
persons aged 55 to 84 years; there was no increased risk for smoking in persons aged 
85 years and older. The authors mentioned that the lack of association in this age-group 
was possibly due to competitive risk factors, and hypothesized that selective survival 
and a decreased response among the oldest persons might have influenced the results. 
To be consistent with the international classification and grading system of AMD,2 
we re-graded the fundus transparencies from the Rotterdam Study. In addition, 
historical data and information from medical records were obtained to exclude other 
causes ofmaculopathy. Re-grading did not alter the overall and age-specific prevalence 
of AMD in the Rotterdam Study. However, re-grading did affect the association 
between smoking and AMD in persons aged 85 years and older. In contrast to the 
former results, smoking is significantly associated with an increased risk of AMD 
(Table 1). 
This is the first observation of an association between smoking and AMD among 
persons aged 85 years and older in a general population.3,4 We conclude, that the 
association between smoking and the increased risk of AMD is irrespective of age. 
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Table 1. Smoking status and age-related macular degeneration (AMD) in two age strata, using the International 
Grading and Classification System for AMD 
Total number of 
Smoking status: 
Never 
Fonner 
Current 
• adjusted for age and gender 
t reference 
55-84 years 
AMD 
present absent 
62 5954 
17 1986 
22 2561 
23 1407 
85 years and over All ages 
Odds AMD Odds AMD Odds 
ratio * ratio * ratio * 
(95% CI) present absent (95% CI)_ present absent (25% CI) 
Lot 
2.1 (1.0-
3.6 (1.6-
36 
23 
6 
7 
282 
184 
70 
28 
l.ot 
0.8 (0.3-2.4) 
5.2 (1.2-23.1) 
98 
40 
28 
30 
6236 
2170 
2631 
1435 
l.ot 
1.5 (0.8-2.8) 
3.5 (1.8-7.0) 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
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Chapter 
Is age-related maculopathy associated with 
Alzheimer's disease? 
The Rotterdam Study 
Abstract 
The authors examined the relationship between age-related maculopathy and 
Alzheimer's disease in the Rotterdam Study, a prospective population-based study 
in the Netherlands. From 1990 to mid-1993, subjects aged 75 years or older 
(n=1438) were screened for presence of age-related maculopathy and Alzheimer's 
disease, and follow-up examinations were conducted from mid-1993 to the end of 
1994. Subjects with advanced age-related maculopathy at baseline showed an 
increased risk of incident Alzheimer's disease (RR 2.1,95% CI 1.1,4.3; adjusted 
for age and gender), but the risk decreased after additional adjustment for smoking 
and atherosclerosis (RR 1.5, 95% CI 0.6, 3.5). These findings suggest that the 
neuronal degeneration occurring in age-related maculopathy and Alzheimer's 
disease may, to some extent, have a common pathogenesis. 
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INTRODUCTION 
Age-related maculopathy (ARM) and Alzheimer's disease (AD) are both chronic 
neurodegenerative disorders that affect a substantial proportion of elderly persons, 
imposing a significant burden on public health and quality of life. In the 
Netherlands, 8% of those aged 75 years and older are affected by end-stage ARMI 
and 13% of those are diagnosed with AD.2 Characteristic of these disorders is the 
irreversible loss of neuronal function, for which there is no cure. 
Although the etiology of both is largely unknown, the pathogeneses of ARM 
and AD show some striking similarities. In ARM, early histopathologic 
manifestations are the extra-cellular drusen deposits and basal laminar deposit. 
These lesions contain lipids, glycoproteins, and glycosaminoglycans, which are 
presumably derived from a degenerating neuroretina.3-6 Accumulation of these 
deposits is associated with deterioration of macular function and subsequent loss of 
photoreceptors.7-9 In AD, an early pathological hallmark is the presence of extra-
cellular senile plaques. These plaques contain p-amyloid, activated microglia, and 
axons and dendrites from dystrophic neurons. 10,1 1 Analogous to those in ARM, these 
deposits are associated with neuronal malfunction and cellloss.ll-13 
The pathogenic parallels between ARM and AD prompted us to study their 
comorbidity within the population-based Rotterdam Study. This study was designed 
to investigate the determinants of various chronic geriatric disorders among middle-
aged and elderly subjects. In the present analysis, we studied the relation of ARM at 
baseline to the two-year incidence of AD among subjects aged 75 years or older. 
SUBJECTS AND METHODS 
Study design and population 
The Rotterdam Study is a population-based prospective cohort study conducted in a 
suburb of Rotterdam, the Netherlands, in which chronic neurologic, 
ophthalmologic, cardiovascular and locomotor disorders are investigated. 14 The 
study was approved by the Medical Ethics Committee of the Erasmus University 
Medical School. Informed consent and permission to retrieve information from 
physicians was obtained from all participants. Baseline interview and screening 
examinations took place from 1990 to mid-1993, follow up examinations were 
conducted from mid 1993 to the end of 1994. 
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Of 10.275 eligible subjects of the entire Rotterdam Study, 7983 (78%) of those 
aged 55 years or older agreed to participate in the baseline phase. In the present 
study, we included only subjects aged 75 years or older (n=2016); of these, 1599 
(79%) underwent a complete screening for ARM and AD. A total of 139 subjects in 
this age group were diagnosed with prevalent Alzheimer's disease in this age group, 
while 22 subjects had a dementia other than AD. Therefore, 1438 subjects were at 
risk of incident AD during the follow-up period and were included in the analysis. 
Diagnosis 
Case-finding procedures for ARM and AD have been described in detail 
elsewhere. I ,2 In brief, during the ophthalmologic screening examination, 35° color 
transparencies were taken of the macular area (Top con TRV-50VT fundus camera, 
Topcon Optical Company, Tokyo, Japan). The diagnosis of ARM was based on 
grading of fundus transparencies according to the international classification 
system. 15 ARM was stratified on the basis of 4 exclusive stages, which increased in 
clinical severity: no ARM, the absence of any type of soft drusen and atrophic or 
neovascular macular degeneration; stage 1, the presence of only soft distinct drusen 
of more than 63 ).tm in the absence of pigmentary irregularities and atrophic or 
neovascular macular degeneration; stage 2, the presence of either distinct drusen 
with pigmentary irregularities or indistinct or reticular drusen; stage 3, the presence 
of indistinct or reticular drusen with pigmentary irregularities; and stage 4, the 
presence of either atrophic or neovascular end-stage macular degeneration. Best-
corrected visual acuity was measured at a distance of 3 m by using a modified Early 
Treatment Diabetic Retinopathy chart. 
Dementia screening and diagnosis at baseline and at follow-up followed a three-
step protocol that included the Minimental-State Examination (MMSE) and the 
Geriatric Mental State schedule, the Cambridge Mental Disorder Examination 
(CAMDEX) diagnostic interview, and an examination by a neurologist, as 
described previously.2 In addition, the entire cohort was monitored during follow-
up to detect cases of dementia by through linking the general practitioner's 
automated medical record system to the database of the Rotterdam Study. Data on 
subjects who could not be rescreened at follow up (refusals, deceased) were 
obtained from informants, medical files, and the regional institute for outpatient 
mental health care. The final diagnosis of AD was based on all collected 
information using NINCDS-ADRDA criteria, 16 which in brief imply the presence of 
dementia not caused by systemic or other brain disorders, deficits in at least two 
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areas of cognition, gradual progression of disease, and no disturbance of consciousness. 
Table 1. Baseline characteristics of subjects at risk of incident Alzheimer's 
disease, stratified by stage of ARM 
Characteristic No ARM Stage 1 Stage 2 Stage 3 
Stage 4 
(n=811) (n=349) (n=165) (n=46) (n=67) 
Age at baseline (years) (SD') 80.5 (4.4) 80.0 (4.0) 81.3 (4.5) 82.2 (5.6) 84.5 (4.8) 
Gender (% women) 64.4 67.9 63.6 67.4 68.7 
Institutionalized (%) 14.8 16 21.2 34.8 34.3 
MMSE' score at baseline (SD) 26.9 (2.2) 26.9 (2.1) 26.8 (2.1) 25.5 (4.8) 26.3 (2.5) 
Smoking Former (%) 35.6 29.1 33.5 30.2 28.4 
Current (%) 12.1 11.8 13 23.3 19.4 
Atherosclerosis (%) 18.3 14.9 22.5 18.6 25 
'SD, standard deviation; MMSE, Mini-Mental State Examination 
Smoking, atherosclerosis, and apolipoprotein E 
Smoking habits were assessed during the baseline home interview; subjects were 
stratified as non-cigarette smokers, former cigarette smokers, and current cigarette 
smokers. The presence of generalized atherosclerosis was evaluated by using the 
ratio of the ankle to brachial systolic blood pressure,17,18 as described previously. 19 
Atherosclerosis was considered present when the left or right ankle-brachial index 
was less than 0.90. Genomic DNA was used for genotyping of apolipoprotein E. 
The apolipoprotein E gene was amplified by using the primers and conditions, as 
described.2o,21 Genotypes E2/E4, E3/E4 and E4/E4 were grouped and defined as the 
presence of the apolipoprotein E4 allele. 
Statistical methods 
The incidence of AD was obtained for the successive stages of ARM. Person-years 
were calculated per age-category after summation of each participant's contribution 
of follow-up time to each category. We calculated the relative risks of incident AD 
for the four stages of ARM as well as for low visual acuity by using Cox 
proportional hazards regression analysis, adjusting for age and gender. Additional 
adjustment for smoking, atherosclerosis, and the presence of the apolipoprotein E4 
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allele was performed in separate analyses. To increase statistical power of the risk 
analyses, ARM stages 1 and 2 were combined, as were stages 3 and 4. 
RESULTS 
Population at baseline 
ARM was absent in 56.4% (n=811) of study subjects. Of the remammg 627 
subjects, 24.3% (n=349) were diagnosed with stage 1, 11.5% (n=165) with stage 2, 
3.2% (n=46) with stage 3, and 4.7% (n=67) with stage 4 ARM. The baseline 
characteristics of these subjects are given in Table 1. In the more severe stages of 
ARM, subjects were older and were more likely to be institutionalized, to smoke, 
and to have atherosclerosis. There were no significant differences in baseline scores 
ofMMSE. 
Incidence of AD 
After an average follow-up period of 25.2 months, 62 incident cases of AD were 
identified. The incidence of AD in the total group of study subjects was 20.0 per 
1000 person-years and ranged from 14.0 per 1000 person years in those aged 75-84 
years to 41.6 per 1000 person-years in those aged 85 years or older. Figure 1 shows 
the crude incidence rates of AD for successive stages of ARM among subjects in 
two age categories. The 2-year cumulative incidence risks, calculated from the 
incidence rates, for all subjects aged 75 years or older were 3.4% for those with no 
ARM, 3.2% for those with stage 1,3.8% for those with stage 2, 9.4% for those with 
stage 3, and 10.0% for those with stage 4 ARM . Women developed incident AD 
more often than men did, but this difference did not reach statistical significance 
(RR 1.7; 95% CI 0.9,3.3; adjusted for age). 
Risk of comorbidity 
After adjustment for age and gender, we found that the risk of incident AD was 
increased for subjects with stage 3 or 4, but not for subjects with stage 1 or 2 ARM 
(table 2). After additional adjustment for smoking and atherosclerosis, the point 
estimate of the relative risk for stage 3 or 4 decreased and the association became 
insignificant. Additional adjustment for presence of the apolipoprotein E4 allele did 
not alter the risk estimates (data not shown). 
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Figure 1. Incidellce rates of Alzheimer's disease (AD), ill persoll-years ;11 two age 
strata, for successive stages of age-related maculopatlty (ARM) as determil/ed at 
baselil/e 
Numbers oJpersoll-yearsJor age stratum 75-84 years: 110 ARM, 1418.7; ARM stage 1, 617,5; ARM 
stage 2,255,6; ARM stage 3, 74,7; ARM stage 4, 64.4. 
Numbers oJpersoll-yearsJor age stratuIII 85+ years: no ARM, 362.1; ARM stage 1, 117.5; ARM stage 
2, 97.8; ARM stage 3 26.8; ARM stage 4, 68.4. 
To investigate whether the association between stage 3 or 4 ARM and incident 
AD resulted from a decline in visual function rather than ARM, we studied the 
association between poor visual acuity at baseline and incident AD. For subjects 
with a best-corrected visual acuity of less than 0.05 the relative risk was 0.96 (95% 
CI: 0.68, 7.05, adjusted for age, age2, and gender), for subjects with a best-corrected 
visual acuity of more than or equal to 0.05 but less than 0.3, the relative risk was 
1.01 (95% CI: 0.35, 2.88). It is therefore unlikely that the observed association 
between ARM and AD can be explained by visual impairment. 
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Table 2. Relative Risk of incident Alzheimer's disease for subjects with 
successive stages of ARM 
No. at baseline 
No ARM 811 
Stage 1 or 2 514 
Stage 3 or 4 113 
• RR, relative risk; CI, confidence interval 
t Adjusted for sex, age, age2 
t Adjusted for sex, age, age2, smoking, and atherosclerosis 
DISCUSSION 
RR' (95% cI')t 
Reference 
1.0 (0.6-1.8) 
2.1 (1.1-4.3) 
Reference 
1.0 (0.6-1.9) 
1.5 (0.6-3.5) 
Based on a general population of elderly subjects, this study shows an association 
between the most severe stages of ARM and incident AD. The nature of this 
association depends partly on smoking and atherosclerosis, which are important risk 
factors for both ARM and AD. 
Strengths of this study include setting, methods of diagnosis and temporal 
design. The population-based setting warranted a valid comparison of study groups 
and reduced the possibility of information bias. The standardized methods of 
diagnosis of both ARM and AD were based on internationally accepted criteria,15.16 
which improved independent case finding. An important part of the design was the 
temporal sequencing of diagnosis of the two diseases. Poor cognitive functioning of 
patients with severe AD generally hampers the performance of extensive clinical 
investigations, and fundus photography is often difficult to carry out. Therefore, we 
considered a cross-sectional analysis of the association between ARM and AD to be 
unreliable. To reduce selection bias, we evaluated the diagnosis of ARM prior to 
the occurrence of AD. The overall incidence of AD in the Rotterdam Study was 
higher than the incidence of this disease in the present study cohort,22 suggesting 
that subjects for whom ARM data were missing were at an increased risk of AD. 
Complete data on ARM for all subjects would have helped to characterize the actual 
association. Neveliheless, this does not explain the associations observed, since the 
lack of complete data generally tends to weaken any relation. 
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Both ARM and AD are complex disorders, in which genetic as well as 
environmental factors have been implicated. Smoking is an established risk factor 
for ARM; the increased risk of incident early or advanced ARM has been estimated 
to be approximately twofold. 23-25 Although former studies suggested an inverse 
relation with AD,26 it has recently been shown that smoking is also associated with 
a two-fold increased risk of incident AD.27 In our analysis, smoking partly explains 
the association between ARM and AD, which may imply that the neurotoxic effect 
of smoking is rather nonspecific. The exact mechanisms are unknown, but altered 
hemodynamic and vascular regulation,28,29 and reduction of oxygen transport into 
the tissue,3o are some of the destructive effects that may be involved. 
Atherosclerosis also partly determines comorbidity of ARM and AD. Earlier 
findings from the Rotterdam Study suggested that generalized atherosclerosis is a 
risk factor for either disease; that is, it was associated with a twofold increased 
prevalence of ARM3! and a 30% increased prevalence of AD.!9 Aside from more 
disease-specific effects such as thickening of Bruch's membrane in ARM32 and 
increased amyloid angiopathy in AD,33 decreased vascular flow and endothelial 
damage are candidate mechanisms by which atherosclerosis may alter both retinal 
and cortical cell function. 
The apolipoprotein E4 allele is associated with both disorders but in an opposite 
way. The presence of this allele has been shown to increase the risk of AD,34, 35 but 
to decrease the risk of ARM. 36, 37 It is therefore unlikely that the apolipoprotein E 
genotype contributes to an association between ARM and AD. In our analyses, 
adjustment for presence of apolipoprotein E4 allele did not distort the relative risk 
estimates. 
In conclusion, the present study suggests that the neurodegenerative diseases of 
ARM and AD show comorbidity, and that smoking and atherosclerosis may be 
causal links. Whether other factors determine a common neurodegenerative 
pathogenesis remains to be elucidated. 
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General discussion 
The aim of this thesis was to expand the epidemiologic knowledge on the etiology of 
age-related maculopathy. The studies that were performed provided data on disease 
occurrence, impact, and genetic and environmental risk factors. This chapter will focus 
on the most important findings, the clinical relevance, and the methodological issues 
of these studies. It will also provide suggestions for future genetic epidemiologic 
research. 
FINDINGS AND CLINICAL RELEVANCE 
Disease frequency and impact 
The occurrence of ARM's late stage, AMD, has been extensively studied in prevalence 
studies. 1-6 All studies found a strong rise with age, and there appeared to be a global 
difference in frequency, and type7 of AMD. Incidence studies were, and still are, 
needed to confirm these findings. In the Rotterdam Study, we studied the incidence of 
AMD at 2-year follow up~ and compared our data with two incidence studies from the 
United States. We found a lower incidence of AMD at all ages, confirming the trend 
that had been suggested by previous prevalence studies. In a recent 'three continent' 
consortium study, we could not find discrepancies in known risk factors to explain this 
issue ("Smith et aI, submitted"). It may be a breakthrough for our understanding when 
these responsible factors are identified. 
The majority of clinical and epidemiological articles on ARM that have appeared 
over the last two decades started with the sentence: 'Age-related macular degeneration 
is the most common cause of blindness in the Western world'. Recent population-
based studies found justification for this statement,8-10 but it was unclear which age 
groups were concerned. In the Rotterdam Study, we studied the importance of ARM 
in relation to visual decline as a function of age. Our data demonstrated that only after 
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the age of75 did the end stages of ARM become the leading cause of blindness. The 
impact grew with further increasing age to a prevalence of 6% of bilateral blindness 
or visual impairment due to AMD in those aged 85 years and over. Whether this 
proportion is sufficient to entitle this disease as a public health problem is a matter of 
debate. Bilateral development of AMD has a great impact on quality oflife, 11.12 and is 
an important reason for elderly to give up independent living. On the other hand, 
dementia and cardiovascular disease are very disabling geriatric diseases with much 
higher frequencies of occurrence13-15 and more implications for nursing care and health 
costs. 
Genetic risk 
Unravelling the genetic basis has recently become a focus of attention in ARM 
research. New statistical methodologies make it possible to dissect complex genetic 
disorders once thought to be unapproachable. The key aim is to identify the 
susceptibility genes in order to gain insight into the molecular basis and perhaps create 
therapeutic starting-points. However, one must know the magnitude of the genetic risk 
to design this kind of research. We performed a familial aggregation study to quantify 
this factor and found that the relative risk of AMD for first degree relatives of AMD 
cases was 4.2 (95% CI 2.6-6.8). Moreover, relatives of cases developed all features of 
ARM at an earlier age, suggesting that presence of a genetic factor was associated with 
earlier onset of disease. We estimated the attributable risk of genetic factors to the 
overall occurrence of AMD to be approximately one fourth. In comparison, the 
strongest known environmental factor, smoking, had a prevalence odds ratio of 3.5 
(95% CI 1.8, 7.0, Chapter 8) and an attributable risk of one fifth in the Rotterdam 
Study. Our genetic risk data will be the basis for the design of further genetic studies, 
and are of clinical importance in genetic counselling of patients. 
Although some reports suggest otherwise, 16 it is rather unlikely that one single gene 
accounts for the overall genetic risk. True evidence of genetic heterogeneity requires 
the identification of all the genes involved - an accomplishment for the future. To 
enhance the current understanding, we attempted to find clues for familial differences 
in risk by calculating risk scores for each family. Our data showed that two thirds of 
the ARM families did not have an excess familial risk, but 17% appeared to have a low 
risk, 14% a moderately increased risk, and only 3% a high risk of disease. These 
findings suggest that only a small fraction of all ARM may be due to mono- or 
oligo genetic factors segregating in some families, and these families will be of 
particular interest to geneticists in the search for genes. 
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Different approaches can be used to dissect the genes determining susceptibility of 
a complex trait. Basically, they fall into two categories: positional cloning and 
candidate gene approach. The former establishes the location of susceptibility loci 
within the genome, while the latter specifically tests whether or not a particular gene 
contributes to the disease. We pursued the latter technique and performed a genetic 
association study to investigate whether the APOE gene contributes to the etiology of 
ARM. 
APOE is a polymorph gene involved in neurodegeneration; the E4 allele increases 
the risk of Alzheimer's disease and Creutzfeldt Jakob disease. 17,18 Contrary to our 
hypothesis, we found a decreased risk of AMD for subjects carrying the E4 allele in 
our study. This unexpected finding was confirmed by a French study, 19 but not all other 
studies could replicate these findings. 20 Our demonstration of the apoE protein in 
drusen and basal laminar deposit provided preliminary evidence of a biological role of 
APOE in retinal neurodegeneration, but this evidence is now growing. Recent mouse 
studies have shown that apolipoprotein E transgenic mice on a high fat diet develop 
significant amounts of basal laminar deposits,21 and that apolipopotein E deficient mice 
have abnormal retinal celllayers.22 Evidence for retinal Muller cells as a production 
site of apolipoprotein E comes from our report as well as from others,23 and it has been 
shown that these cells increase expression in case of retinal damage. 24 
There are various possibilities with regard to the underlying mechanism of the role 
of APOE in ARM. Firstly, apolipoprotein E may have a neurotrophic effect by its role 
of redistributor of lipids and cholesterol from degenerating neurons to form new cell 
membranes. The latter are necessary at a constant rate for remodelation of 
photoreceptors,z5 Secondly, apolipoprotein E may be needed to clear Bruch's 
membrane of lipids and other waste products from the retinal pigment epithelium 
which may otherwise facilitate the development of drusen and basal laminar deposit. 
Thirdly, apolipoprotein E has anti-oxidative capacities26 and may interact with lipid 
peroxidation of photoreceptor membranes occurring in light absorption. At this 
moment we do not have an explanation for the direction of the genetic risk association, 
but isoform differences in binding capacity, internalization and degradation of lipids, 
as well as differences in anti-oxidant activity may be important. 
Environmental risk and comorbidity 
An earlier report of the Rotterdam Study showed that smoking was a risk factor for 
AMD in subjects aged 55-84 years, but not in subjects aged 85 years and over.27 This 
was an unexpected finding for which we did not have a good explanation. After we 
improved the diagnosis of ARM by regrading baseline fundus transparencies using 
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ophthalmic history data and criteria of the International Classification System,28 we 
reanalyzed the smoking data. Now, we also found a relation with smoking among those 
aged 85 years and older. 
Smoking is undoubtedly the most established environmental risk factor of ARM to 
date. A large number of epidemiologic studies have reported a strong relation between 
smoking and prevalent AMD,29-31 two studies showed a relation with incident ARM as 
reported by medical physicians,32,33 and a recent study by Klein et a1. reported an 
association with incident early ARM as diagnosed on fundus transparencies. 34 Several 
mechanisms have been suggested to explain the association. Because smoking 
decreases plasma antioxidant levels35,36 as well as luteal pigments in the human retina,37 
it may increase the risk of damage to the macula by light and oxidative stress. Another 
explanation may be that smoking causes maculopathy by promoting atherosclerotic 
damage to the choroidal vessels; atherosclerosis has been shown to be associated with 
AMD.38 Lastly, smoking may aggravate retinal degeneration by liberation of 
arachidonic acid, with subsequent initiation of an inflammatory response.39 In line with 
this pathway is the finding that nicotine and cotinine activate phospholipase A2 present 
in photoreceptor membranes with formation of arachidonic acid. 40 
The pathogenesis of ARM shows some striking similarities with Alzheimer's 
disease (AD). In fact, some researchers refer to ARM as 'the Alzheimer of the eye'. 
Both disorders are characterised by precursor lesions that are presumably derived from 
degenerating neurons, subsequently leading to neural malfunction and cell loss. 
Moreover, vascular insufficiency, smoking, apolipoprotein E and oxidative stress 
appear to be causal links in both disorders. Our studies showed that subjects with 
severe stages of ARM had an increased risk to develop Alzheimer's disease, but it 
appeared that most of this relation could be ascribed to the shared risk factors smoking 
and atherosclerosis. These findings do not have clinical consequences since adequate 
therapy is not available, but it may be relevant for caretakers to be cognisant of the 
relationship_ Deducing from our data, it is not to be expected that the two disorders 
have significant genetic factors in common. 
METHODOLOGICAL CONSIDERATIONS 
Study design 
All studies described in this thesis were observational studies based on a large study 
population derived from a general Dutch population. One of the great benefits of this 
type of design is that a great variety of different diseases as well as risk factors can be 
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studied, that their general distribution can be evaluated, and that study results can 
easily be generalized. Among the drawbacks are the large enterprise, and the relative 
infrequency of outcomes despite the substantial number of study subjects. 
We applied a cross-sectional design in chapters 3, 7, and 8. Cross-sectional studies 
are generally less preferable than longitudinal studies, because they are limited in the 
interpretation of causality. In practice, they are often the initial phase of a longitudinal 
study, and can be used to generate hypotheses which can be tested in follow up phases 
later on. In chapter 4, the aim was to assess disease impact, and a cross-sectional 
design was therefore appropriate. In chapter 7, the aim was to assess the association 
between the APOE gene and AMD. The APOE genotype is an exposure that does not 
alter over time, so the current information on the APOE gene is as useful as any. 
However, because this gene may be related to survival,41 it is recommended that our 
investigation is replicated with incident AMD cases. In chapter 8, the aim was to assess 
evidence for a causal relation between smoking and AMD. Smoking is not a stable 
exposure, and ideally there should have been a time-interval between the 
measurements of exposure and disease corresponding to the latency period. Although 
the consistency of findings among studies adds to the evidence of a true relation, 
replication by many more well described incidence studies is needed to confirm the 
findings and to establish a better estimate of the strength of the association. 
We applied a longitudinal design in chapters 3 and 9, using incident data from 2 
years follow up. Obtaining stable estimates of incidence requires a substantial person-
time experience, and a more lengthy follow up time is generally preferred. In chapter 
3, the aim was to describe the natural course of ARM, and incidence oflate stages. The 
short follow up period was very suitable to investigate all the steps involved in the 
development of ARM. However, a longer follow up time will be needed to increase the 
number of incident cases and the precision of the incidence rate estimate. In chapter 
9, the aim was to assess the relation between ARM and incident Alzheimer's disease. 
Although the association will be reinvestigated with more incident cases in the future, 
the substantial number of incident Alzheimer's cases allowed for reasonable risk 
estimates. 
We applied a so-called reconstructed cohort design42 in the genetic-epidemiologic 
studies described in chapters 5 and 6. This design is a true hybrid of a case-control and 
a cohort design. In chapter 5, the familial aggregation study was initiated with the 
selection of index cases and controls, while their relatives were subsequently 
assembled in cohort form. Relatives of cases were considered to be the exposed cohort, 
relatives of controls the non-exposed cohort, and the two cohorts were analyzed in life 
tables. For this procedure, it was necessary to pool relatives from different families, to 
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disregard the family unit, and to ignore the possibility of heterogeneity. In chapter 6, 
we performed a supplementary analysis on the same data to make up for these 
drawbacks. We now respected the family unit and calculated family scores based on 
observed and expected number of affected relatives. Small families sizes, as well as a 
small number of families, create a problem for this approach, because it decreases the 
power to achieve statistical significance across risk strata. 
Validity 
Selection bias occurs when participation in a study is influenced by correlates of the 
disease or the determinant. It causes distortion of the true relation; in other words, the 
relation between exposure and disease differs for those who participate in the study 
from those who are eligible but do not participate. Lost to follow up is an important 
source of selection bias for cohort studies, especially when response rates are low. The 
overall response in the Rotterdam Study was reasonable to good with 78% and 79% 
at baseline and at 2-years follow up, respectively. However, comparison between 
participants and nonparticipants learned that nonparticipants were older, more likely 
to be diseased, and more severely affected. Assuming that we selected a relatively 
healthy cohort, the prevalence and incidence of ARM may be higher in reality than in 
our studies. We do not think that non-response has influenced the direction of the risk 
for the associations with apolipoprotein E, smoking, and Alzheimer's disease, because 
the associations are likely to be more pronounced in more severely affected subjects. 
However, it may have caused an underestimation. In the familial aggregation study, the 
response rate was 84% and similar for cases and controls. Nonparticipants did not visit 
ophthalmologists more often than participants did. Thus, we think it is unlikely that 
non-response has distorted estimates of the genetic risk. 
Misclassification of outcome or determinants may lead to information bias. 
Misclassification that is non-differential, that is, which is randomly distributed over the 
compared groups, leads to dilution of the effect towards the null-value. In this thesis, 
we made a great effort to classify the outcome as correct as possible. We collaborated 
with the Beaver Dam Eye Study to learn the specifics about the ARM grading rules, 
and regraded all the baseline macular transparencies using the protocol of the 
International Classification System and all existing ophthalmologic information to 
diagnose ARM. Our diagnoses of AMD were judicated by investigators from the 
Beaver Dam Eye Study and Blue Mountain Eye Study. Furthermore, we regularly 
tested inter- and intra-observer variation of ARM grading, and repeated consensus 
training when weighted kappa values were unacceptable. These procedures improved 
the baseline ARM classification especially in the older subjects, which enabled us to 
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detect an association with smoking in this age group. Most determinants were 
measured using standardized and generally approved protocols, but non-differential 
misclassification of risk factors and confounders cannot be totally excluded. 
We do not think that differential misclassification distorted results, because the 
assignments of determinants and outcome were independent of each other and data-
collection occurred in a symmetrical fashion. An exception to this may be the results 
of the logistic regression analysis in the familial aggregation study. Here, 
misclassification of the disease status among control relatives may have affected the 
prevalence odds ratio's, because these relatives were slightly younger and developed 
ARM at a later age than case relatives. In the Kaplan-Meier analysis, non-affected 
subjects were censored at age at examination, and we therefore think that it is unlikely 
that differential misclassification has influenced these risk estimates. 
Confounding bias occurs when the association under study can be explained by an 
extraneous factor that is not an intermediary in the causal chain. A confounder must 
be associated with the disease under study as well as with the exposure under study to 
be confounding. In all the studies described in this thesis, age was probably the most 
important confounder. It is the strongest risk factor of ARM, and related to most 
determinants that we studied. We controlled for the effect of age in most analyses by 
stratification in various age groups and by adding this factor in a multivariate model. 
Where appropriate, we dealt with other confounding factors as atherosclerosis, 
smoking, and APOE in the same way. Theoretically, the factors smoking and 
atherosclerosis may be intermediate factors of the relations under study in chapters 5, 
7, and 9. Adjustment for these factors may then have led to overadjustment, taking 
away most of the effect. We handled this problem by comparing the results with and 
without these factors. Only in chapter 9 did adjustment for these factors attenuate our 
estimates, which may suggest that smoking and atherosclerosis are causally important 
in the relation between ARM and Alzheimer's disease. In future analyses, more 
sophisticated techniques as G-estimation43 may be used to further study these factors. 
FUTURE RESEARCH 
Disease frequency and impact 
The prevalence of AMD is now quite well established in western Caucasian 
populations, but not in many other populations. Reports among subjects from Chinese 
origin suggesting a high registry of pigment epithelial detachments7 call for well-
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designed surveys in Asian populations. The racial differences in early and late signs 
of ARM44,45 need further investigation. In addition, incidence studies with long follow 
up periods are needed throughout the world. Eventually, global comparisons of these 
studies registering occurrence, life styles, environmental influences, and genetic 
background will provide more insights into the causal pathway. 
Our findings regarding disease impact indicate that blindness due to the end stages 
of ARM is common in a population of those aged 75+ years. With the growing life 
expectancy this is a rather grey perspective, especially when there are no means to 
change this fate. There is a clear need for preventative and therapeutic strategies, but 
until research has advanced to that stage, efforts should now be made to improve the 
impaired functional status, independence, and quality of life of AMD patients. Optical 
magnifiers using new computer and television technology, or even intra-ocular devices, 
are a way of alleviating impairment,46 but teaching patients how to cope with their 
handicap using the remaining visual field and other senses for daily tasks may improve 
quality of life just as well. Investigations evaluating these modalities and their cost-
effectiveness will lead to better management of patients in the near future. 
Genetic Risk 
Our findings provide clues for the magnitude of the genetic risk and its heterogeneity. 
It is now a challenge to dissect the genes that are responsible for this risk. 
Conventional parametric linkage analysis ideally requires large pedigrees with multiple 
generations affected. Using this technique, a potential ARM-locus was detected on 
chromosome 1 in a large multigenerational family with ten subjects with either large 
confluent drusen or geographic atrophy.56 Current research is aiming at refinement of 
this locus and identification of the gene, and others are momentarily investigating this 
locus for confirmation. Linkage analysis using multigenerational families with ARM 
will continue to be a powerful tool to identify genes in the future, but these families are 
difficult to find. 
Other techniques known as allele-sharing methods have been developed to 
overcome this problem.48 The aim is to show that affected relatives inherit identical 
copies of a genomic region more often than expected by chance. A great benefit is that 
this method is non-parametric: it requires no assumptions about mode of inheritance 
or number of genes. Affected sib-pair analysis is the simplest form of this method, but 
newer versions take more distantly related relatives into account. At present, several 
research groups are collecting affected relative pairs, and all have difficulty in 
estimating the necessary size of the study population. In the complex diseases 
Alzheimer's disease and non-insulin dependent Diabetes Mellitus, a size of 150-300 
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sib-pairs was sufficient to show linkage, but, presumably, even more are required for 
ARM.49 
Association studies investigating candidate genes do not concern familial 
inheritance patterns at all. These studies handle the genes of interests as regular 
exposures using epidemiologic designs like the case-control study. All the pitfalls that 
affect validity in traditional epidemiologic research playa role in these studies, and 
especially the choice of a control population is crucial in avoiding selection bias. 
Examples of this candidate gene approach is the study by Allikmets et a1.52 
reporting associations with variations of the Stargardt's disease gene ABCR. In this 
study, the coding regions of the ABCR gene were screened for sequence variations in 
a group of unrelated ARM subjects, and these variations were compared with a control 
group consisting of non age-matched subjects from the general population collected 
for other studies. Overall, there was no statistically significant difference in frequency 
of variants between the two groups (36% vs 31 %, P=O.3). However, 13 of the 18 
sequence variations were found more frequently in the ARM group, and the authors 
claimed that these were 'AMD-associated'. Moreover, they suggested that ABCR may 
be a dominant susceptibility locus for AMD because a heterozygous older adult in a 
Stargardt family had developed AMD. A major discussion started after the publication 
of this study concerning flaws in design, analysis, and far-reaching conclusions, which 
highlighted the challenges of candidate gene analysis. 51 .52 The debate accrued even 
more when two other research groups,53,54 failed to find an association with ABCR in 
their case-control studies, while a French study confirmed heterozygous ABCR 
mutations in three grandparents of Stargardt families. 55 Allikmets et al. are 
momentarily involved in an international survey using more accepted diagnostic 
criteria to investigate the frequencies of the two most pronounced ABCR variants. 56 
More studies will be needed to establish the role of ABCR in AMD; these could be 
well-designed association studies, family studies investigating cosegregation of the 
specific ABCR variant and disease, molecular studies showing affected protein 
structure, function, or expression, and perhaps in vitro or laboratory studies 
demonstrating altered gene effects which could be related to ARM. 
Research regarding the apolipoprotein E gene should basically follow the same 
course. Already laboratory studies are evolving to investigate the retinas of APOE 
deficient or transgenic animals. More clinical as well as laboratory studies are needed 
to investigate the retina-specific effects of the E2, E3, and E4 alleles, for this is as yet 
not understood. 
Considering the fast genetic progress, it is to be expected that at least some of the 
ARM susceptibility genes will have been identified in the near future. This will then 
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start off a whole new cascade of research, including genetic epidemiology. Once a 
gene has been identified in a specific family or patient population, the next step may 
be to investigate the distribution of this gene in more general populations. If the gene 
occurs at a considerable rate in those populations, one may want to know if gene 
expression can be modified, and investigate the relation with environmental factors. 
This will lead to a better understanding of the mechanisms involved, and may provide 
'life-rules' for high-risk individuals. 
Environmental risk 
Future environmental research should focus on identification of risk factors that 
provide insight into the etiology of ARM, and preferably on those that are amenable 
to change. It is important to know how smoking increases the risk of end stage ARM, 
and at what stage of early ARM one should stop smoking to alter this risk. Nutrition 
comprehends a large range of environmental risk factors that are potentially 
modifiable. Most current knowledge is based on cross-sectional analyses of data, and 
future analyses should make use of incident ARM. When certain food factors or 
supplements show a stable association in these analyses, intervention research as 
randomized clinical trials may be initiated to establish a definite causal relationship. 
Another risk factor that can be influenced is cataract extraction. Well-designed 
prospective studies are necessary to study the causality of this relation, and to 
investigate whether any surgical procedures may prevent the increased risk of 
subretinal neovascularization. 
Only little susceptible to change, but interesting from an etiologic point of view are 
the vascular factors hypertension, atherosclerosis, and estrogens. Incidence studies are 
also necessary to verify their etiologic role in ARM, and to learn about the mediating 
mechanism. Although other ARM research areas are investigating this relation,57-59 
more studies are needed which incorporate histopathologic and pathofysiologic data 
in good clinical epidemiologic studies. This may help elucidate the consequences of 
atherosclerosis, such as decreased choroidal vascular flow, diminished passage of 
nutrients and oxygen, increased lipid deposition in Bruch's membrane, accumulation 
of deposits and membranous debris, clumping of pigment, new vessel formation and 
loss of photoreceptors. 
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FINAL REMARK 
I hope our studies help improve the insights into the causes of ARM, and stimulate 
research to further investigate the pathogenesis of ARM. What may be the benefits? 
The challenges are knowledge of pathologic mechanisms, insight into gene functions, 
identification of individuals at risk, development of public health measures, better 
patient management, and new therapeutic options. 
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Summary 
Part I - Background 
Chapter 1 describes the aims of our studies. ARM is a retinal disease causing a central 
scotoma in the visual field. There are currently no therapeutic modalities that restore 
this loss of vision. The ultimate goal of this thesis was to gain more insight into the 
causes of ARM. For this purpose, we performed genetic epidemiologic investigations 
based on subjects selected from the Rotterdam Study. 
Chapter 2 provides a review of the previous epidemiologic studies on ARM. The 
general notion is that genetic factors are important in the disease etiology, but to what 
extent is unclear. Smoking is the most-established environmental factor associated with 
the disease to date. 
Part II - Disease frequency and impact 
Chapter 3 reports on the incidence of the end stages of ARM, also called AMD, and 
on the natural course of the disease. In 2 years, 2 per 1000 subjects of our total study 
population developed AMD. Subjects older than 85 years, and subjects with indistinct 
drusen and RPE-alterations in the macular area were most at risk. The early stages of 
ARM appeared to progress in a distinct pattern at a stable rate. 
Chapter 4 shows data on the consequences of ARM with regard to visual function. 
The end stages were the most frequent cause of bilateral blindness after the age of 75 
years, and the proportion of subjects blind due to AMD increased significantly with 
further rising age. In subjects aged 85 years and older, one fourth of all blindness was 
caused by AMD. 
Part III - Genetic risk of ARM 
Chapter 5 reports on the magnitude of the genetic component. In a familial 
aggregation study, we estimated that the lifetime relative risk of AMD for first degree 
relatives of affected subjects was 4.2 (95% CI 2.6, 6.8). Furthermore, we calculated 
that approximately one fourth of all AMD in the general population can be attributed 
to genetic factors. 
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Chapter 6 describes the familial risk in greater detail. The increased risk of ARM was 
not the same among families. On the contrary, we demonstrated that there are low, 
intermediate and high risk families. The data suggest that only a small fraction of all 
ARM is caused by a strong genetic component. 
Chapter 7 provides evidence for a genetic association with the APOE gene. APOE had 
been associated with other neurodegenerative disorders, which prompted us to study 
its relation with AMD. Subjects with the E4 allele were at a significantly decreased risk 
of AMD, while subjects with the E2 allele had a slightly increased risk. Since the 
association was not immediately understood, we investigated whether the apoE protein 
was present in the macula of the eye. In an immunohistochemical study in human post-
mortem eyes, we demonstrated that apoE was particularly present in soft drusen and 
basal laminar deposit, the pathological hallmarks of ARM. 
Part IV - Environmental risk and comorbidity 
Chapter 8 gives a supplement to an earlier investigation in the Rotterdam Study. In 
this analysis, we demonstrated that the relation between smoking and AMD is 
independent of age. The relation was also present in subjects aged 85 years and over. 
Chapter 9 shows that ARM and Alzheimer's disease have certain risk factors in 
common. Subjects with severe ARM had an increased risk of incident Alzheimer's 
disease, but this relation was mostly determined by smoking and atherosclerosis. 
Part V - General discussion and summmy 
Chapter 10 provides the general discussion on all the studies described in this thesis. 
In this chapter, strategies for future research are discussed. 
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Samenvatting 
Dee! 1 - Achtergrond 
Hoofdstuk 1 beschrijft de doelstellingen van dit promotie-onderzoek. Leeftijd-
gebonden maculopathie, ook wel ouderdoms maculopathie genoemd, is een ziekte van 
het netvlies die een zwarte vlek in het centrum van het gezichtsveld veroorzaakt. Er 
zijn momenteel nog geen therapeutische mogelijkheden om dit gezichtsverlies te 
herstellen. Het doel van dit proefschrift was om de kennis omtrent de oorzaken van 
leeftijd-gebonden maculopathie te vergroten. Hiertoe verrichtten wij genetisch 
epidemiologische studies gebaseerd op personen die deelgenomen hadden aan het 
ERGO-onderzoek (Erasmus Rotterdam Gezondheid voor Ouderen). 
Hoofdstuk 2 geeft een overzicht van voorgaande epidemiologische studies naar 
maculopathie. De huidige mening is dat deze ziekte genetische oorzaken heeft, maar 
het is nog onduidelijk in welke mate genen het risico op de ziekte bepalen. Roken is 
momenteel de belangrijkste omgevings factor die geassocieerd is met maculopathie. 
Dee! 2 - Frequentie en gevolgen van de ziekte 
Hoofdstuk 3 rapporteert de incidentie van de eindstadia van leeftijd-gebonden 
maculopathie, ook wel maculadegeneratie genoemd. Tevens wordt het natuurlijk 
verloop van de ziekte beschreven. In 2 jaar ontwikkelden 2 op de 1000 person en in 
onze studie maculadegeneratie. Personen ouder dan 85 jaar, en personen met onscherp 
begrensde drusen (witte vlekjes) op het netvlies met veranderingen van het retinaal 
pigmentepitheel, hadden het grootste risico om maculadegeneratie te krijgen. De 
progressie van de vroege stadia van maculopathie bleek volgens een vast stramien te 
verlopen. 
Hoofdstuk 4 geeft de consequenties van de ziekte voor het zien weer. 
Maculadegeneratie was de meest frequente oorzaak van bilaterale blindheid na de 
leeftijd van 75 jaar, en het aandeel van maculadegeneratie in de totale blindheid nam 
nog verder toe met de leeftijd. In personen ouder dan 85 jaar was maculadegeneratie 
verantwoordelijk voor een kwart van aIle blindheid. 
Dee! III - Genetisch risico op !eeflijd-gebonden maculopathie 
Hoofdstuk 5 beschrijft in welke mate maculadegeneratie genetisch bepaald is. Wij 
berekenden in een familie aggregatie onderzoek, dat het risico op de ziekte voor eerste 
graads familieleden van aangedane personen ruim vier keer verhoogd is. Tevens 
schatten wij, dat ongeveer een kwart van aIle maculadegeneratie in de algemene 
bevolking door genetische factoren veroorzaakt wordt. 
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Hoofdstuk 6 geeft een meer gedetailleerde beschrijving van dit genetisch risico. Niet 
aIle maculadegeneratie families bleken dezelfde kans op de ziekte te hebben. 
Integendeel, wij toonden aan dat er families waren met een laag risico, een 
middelmatig verhoogd risico, en een sterk verhoogd risico. Onze gegevens suggereren 
dat slechts een klein deel van aIle maculadegeneratie door een sterke genetische factor 
bepaald wordt. 
Hoofdstuk 7 levert bewijs voor een genetische associatie met het apolipoproteine E 
gen. Uit eerder onderzoek bleek dit gen belangrijk voor neurodegeneratieve ziekten, 
zoals de ziekte van Alzheimer. Dit inspireerde ons om de rol van apolipoproteine E bij 
maculadegeneratie te onderzoeken. Wij vonden dat personen met het E4 allel een lager 
risico op de ziekte hadden dan personen met het norma Ie allel. Omdat ons niet geheel 
duidelijk was of dit gen daadwerkelijk bij de ziekte betrokken is, onderzochten wij of 
het apolipoproteine eiwit aanwezig is in de macula. In een immunohistochemische 
studie op post-mortem verkregen humane ogen, toonden wij het eiwit aan in die 
structuren, die bepalend zijn voor leeftijd-gebonden maculopathie. Onze gegevens 
suggereren dat het apolipoproteine E gen een rol speelt in het ontstaan van 
maculopathie. 
Deel IV - Omgevings risico en comorbiditeit 
Hoofdstuk 8 is een aanvulling op een eerder verschenen artikel van het ERGO-
onderzoek. In deze analyse lieten wij zien, dat de relatie tussen roken en 
maculadegeneratie onafhankelijk is van leeftijd. Ook rokers ouder dan 85 jaar hadden 
een verhoogd risico op maculadegeneratie. 
Hoofdstuk 9 laat zien dat het ontstaan van leeftijd-gebonden maculopathie 
overeenkomsten heeft met de ziekte van Alzheimer. Personen met emstige vormen van 
maculopathie hadden een verhoogd risico om de ziekte van Alzheimer te ontwikkelen, 
maar deze relatie was met name bepaald door roken en aderverkalking. Deze factoren 
lijken gezamenlijke risico factoren te zijn. 
Dee! V - Algemene discussie en samenvatting 
Hoofdstuk 10 bediscussieert aIle bevindingen van dit proefschrift. Ook worden in dit 
hoofdstuk aanbevelingen gedaan voor verder onderzoek. 
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Dankwoord 
Veel mensen zijn betrokken geweest bij de totstandkoming van dit proefschrift en 
mijn promo tie. Ik wil hen graag bedanken. 
Prof. Dr. P.T.V.M. de Jong en Prof. Dr. A. Hofman, promotores. Paulus, jou wil 
ik danken voor je enorme inzet voor het onderzoek, je directe aanpak, 
besluitvaardigheid, en de vrijheid die je me gaf om het onderzoek in te vullen. Je 
bereikbaarheid en de snelheid van het nakijken van manuscripten in de vaak strakke 
tijdsplanningen heb ik zeer gewaardeerd. Bert, jouw enthousiasme voor de 
epidemiologie vind ik aansteke1ijk. Ik heb veel geleerd van jouw benadering t.a.v. 
het opzetten van onderzoek en analyseren van gegevens. De discussies tijdens onze 
vergaderingen zijn goed voor het onderzoek en goed voor mij geweest. 
Commissie1eden. Dr. C.M. van Duijn, Cock, jij hebt een cruciale rol gespeeld 
voor het bepalen van de richting van mijn onderzoek. Mede door jou zijn de juiste 
dingen op de juiste tijd gebeurd, en hebben mijn manuscripten een betere lading 
gekregen. Jouw cursussen moest ik soms meer dan eens volgen, maar daama 
hebben ze mij voorgoed warm doen lopen voor de genetische epidemiologie. Prof. 
R. Klein, Ron, you and your research group taught me all there is to know about 
ARM grading. I thank you and Barbara for your friendship and hospitality, and am 
grateful for all your good advice in the design and analyses of our studies. Dr. J.R. 
Vingerling, Hans, jij was mijn voorganger en voorbeeld in veel zaken. Onze 
brainstorm sessies yond en vind ik nog steeds gewe1dig, en ik dank jou en Greet 
voor alle happen en het luisterend oor. Ik hoop dat we nog lang zullen samen 
werken. Prof. Dr. G. Van Rij, Dr. C.B. Hoyng, Prof. Dr. U. Chakravarthy, en Prof. 
Dr. F.R. Rosendaal wil ik bedanken voor het zitting nemen in de promotie 
commlSSle. 
De ERGO-ogen groep: Roger Wolfs, Jacqueline Assink, Ada Hooghart, Corina 
Brussee, Raan Ramrattan, Gerard de Bruyne, Caroline Hulsman, Petra Borger, en 
Redmer van Leeuwen. Roger, met jou als glaucoom-counterpart heb ik gedurende 
het hele onderzoek erg prettig samengewerkt. Wij vormden een goed team. Ik 
waardeer het zeer dat je de layout van mijn proefschrift wilde doen, terwijl je wist 
waar je aan begon. Jacqueline, ik heb altijd veel plezier in het uitdagende aspect van 
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van onze samenwerking en vriendschap. Jij wist altijd veel van zaken waar ik juist 
niets van af wist, en in onze discussies ging het er vaak hard maar constructief aan 
toe. Ik wil jullie beiden bedanken voor de eindsprint die we gezamenlijk trokken, 
en ben verheugd dat jul1ie mijn paranimfen willen zijn. Ada en Corina, jul1ie waren 
van vitaal belang voor onderzoek en gezel1igheid. Zonder jullie geen ERGO data, 
geen familie data, geen ARM gradering, en geen boekje. Ik heb vaak een beroep op 
jullie gedaan, en dank jul1ie voor jullie hulp, ideeen, en flexibele opstel1ing. Raan, 
jou dank ik voor je bereidheid bij tijd en wijlen de advocaat van de duivel te 
spelen. Jouw gevoel voor humor ben ik erg gaan waarderen. Gerard, ik dank jou 
voor al die uren die jij besteed hebt aan het gradeer-klaar maken van de dia's. 
Opvolgers Caroline, Petra en Redmer wens ik een goede resterende AIO tijd toe. 
Andere ERGO- en Epi-medewerkers. Initiators en onderzoeks1eiders Rick 
Grobbee, Huib Pols, Jacqueline Witteman, Monique Breteler, en Deirdre van der 
Kuip wil ik bedanken voor het realiseren van ERGO. Met artsen en onderzoekers 
van diverse generaties, Martine de Bruijne, Maarten de Rijk, Alewijn Ott, Huib 
Burger, Paul van Daele, Sandra Kalmijn, Carl Moons, Ronald Stolle, Michiel Bots, 
Anske van der Born, Caroline van Rossum, Marianne Geleijnse, Sesmu Arbous, 
Iris Westendorp, Jan Cees de Groot, Piet Post, Nicole van Pope1e, Frank-Erik de 
Leeuw, Angelique Weel, Casper Bijkerk, en Sanjah Harhangi heb ik in die zes jaar 
een leuke tijd gehad. Op ERGO zelf was het altijd gezel1ig met Lydia Buist, 
Margriet van Rees, Inge Haumersen, Toos Stehmann, Hilda Komman, Ria 
Rijneveldshoek, Micheliene de Haas, en Agnes van der Voom. Anneke Korving, 
jou wil ik bedanken voor al je regelwerk maar ook voor de 101 op ERGO. Je was 
een goede vliegende keep als we eens een hand tekort kwamen. De 'jongens' van 
de automatisering Rene Vermeeren, Eric Neeleman, Marcel Eijgermans, Michael 
Koenders, Hanneke den Breeijen, Nano Suwamo, en Frank van Rooy waren zeer 
essentieel. Ik dank met name Rene voor de bereidheid om in onmogelijke 
tijdsbestekken mijn data sets analyse klaar te maken. Elly van der Heiden en Lilian 
Verwey dank ik voor al hun werk achter de schermen. Statistici Theo Stijnen, Wim 
Hop, en Paul Mulder wil ik bedanken voor hun efficiente en adequate wijze van het 
invullen van statistische scotomen. Jeanine Houwing wil ik bedanken voor de 
aanwijzingen bij de analyse van hoofdstuk 6. Peter Boerlage, Jolanda Bekker, en 
El1y van Vliet dank ik voor het oplossen van veel aanstellingszaken. 
De oogpoli. De staf en al1e medewerkers van de poli dank ik voor hun 
belangstel1ing voor mijn onderzoek en hun bereidheid af en toe een oogje dicht te 
doen als ik mij onzichtbaar maakte. Lous Ruempol, jou wil ik bedanken voor je 
hartelijkheid en je hulp bij regelingen in het begin van het onderzoek. Op mijn 
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collega assistenten Leo de Jong, Rob Geerling, Roger Wolfs, Raan Ramrattan, 
Lieneke Dijkstra, en Marjolijn Bartels, kon ik, ook in matige tijden, altijd rekenen. 
Mijn vriendinnen dank ik voor hun vriendschap en meer. Jacqueline, Frederique, 
Marja, Cora, en Katrin zou ik niet willen missen. Marja, jou wil ik met name ook 
bedanken voor veel zaken buiten de kaft. Mijn roeimaatjes in Leiden en Rotterdam 
dank ik voor de vele sportieve tijden binnen en buiten de boot. 
Maarten, jou wil ik bedanken voor heel veel goede dingen. Jouw ideeen zijn op 
veel plaatsen in dit proefschrift terug te vinden. Bert-Jan, Anneli, Margreet en Paul 
wi! ik bedanken voor een altijd warm onthaal. 
Van mijn lieve ouders heb ik geleerd het leven open te benaderen en door te 
zetten. Ik dank jullie voor alle mogelijkheden die jullie mij boden, en wi! daarom 
graag dit boekje aan jullie opdragen. Ook dank ik mijn zussen Liesbeth, Heleen, en 
Gabrielle voor al hun support. 
Laat die eeuw nu maar komen. 
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